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Abstract 
The purpose of this study was to determine whether naïve Bayesian artificial intelligence could 
accurately predict clinical decisions made during the referral refinement of Chronic open angle 
glaucoma (COAG) by three specialist independent prescribing optometrists using the highly 
structured standard operating procedure (SOP) adopted by the Community Ophthalmology Team 
(COT) of the West Kent Clinical Commissioning Group (CCG). The effectiveness of the COT, in 
terms of reducing false positive referrals and costs to the National Health Service (NHS), was also 
explored. This was the first study of its kind. 
Treating the study as a clinical audit allowed collection of unconsented fully anonymised data from 
the worst affected eyes or right eyes of 1006 cases referred into the COT. Each case was classified 
according to race, sex, age, family history of COAG, reason for referral, intraocular pressure and its 
inter-ocular asymmetry (Goldmann Applanation Tonometry), several optic nerve head dimensions 
(vertical size, cup disc ratio and its inter-ocular asymmetry; dilated stereoscopic slit lamp 
biomicroscopy with Volk lens), central corneal thickness (ultrasound pachymetry) and the severity of 
any visual field defects (Humphrey Visual Field Analyser, SITA FAST 24-2 testing strategy, Hodapp-
Parrish-Anderson classification). Grouping of data into multiple cut-off points was informed by 
previous research and National Institute for Health and Care Excellence (NICE) guidelines. 
Preliminary analyses showed that most cases (79%) were discharged, 7% were followed up and 
14% were referred to the NHS hospital eye service. The high discharge rate led to NHS cost 
savings of over £50 per case. Previous reports of increased intraocular pressure with central 
corneal thickness and increased cup disc ratios with cup disc size were also confirmed.  
Despite a high degree of inter-dependency between clinical tests, which violated the key 
assumption of naïve Bayesian analyses, the scheme learned rapidly and its weighted accuracy, 
based on randomised stratified tenfold cross-validation, was high (95%, 2.0% SD). However, false 
discharge (3.4%, 1.6% SD) and referral rates (3.1%, 1.5% SD) were considered unsafe. Making the 
analysis cost sensitive led to an 80 fold increase in COT follow-ups that would have reduced cost 
effectivity. The transferability of likelihood ratios was explored along with their use, compared to Chi-
square, to rank clinical tests and explore redundancy in the SOP adopted by the COT.  
In summary, high discharge rates were consistent with the level of false positive referrals for 
suspected COAG reported in the literature and reduced NHS costs. Although use of a structured 
SOP led to high accuracy, naïve Bayesian artificial intelligence could not safely predict the decisions 
of COT optometrists as it caused too many false discharges and referrals. More sophisticated forms 
of machine learning need to be explored. 
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Chapter 1: Background 
1.1 Introduction  
Previous research carried out at Aston University had indicated that artificial intelligence based on 
naïve Bayes’ theorem (referred to as Bayes from now on) could replicate diagnoses made by an 
experienced optometrist with a high level of accuracy as long as a suitable Standard Operating 
Procedure (SOP) was adopted (1).  The aim of the study described in this thesis was to determine 
whether this was true by applying Bayes to clinical data collected by a Community Ophthalmology 
Team (COT) which had developed a SOP for the referral refinement of suspected Chronic Open 
Angle Glaucoma (COAG, also known as Primary Open Angle Glaucoma, POAG).  Chapter 1 
provides a brief review of Bayes in relation to ophthalmic research before describing how it was 
applied in the present study.  A review of the literature relating to COAG follows prior to describing 
the current guidelines for its detection and management, issued by the National Institute for Health 
and Care Excellence (NICE).  The review moves on to the referral refinement of COAG by 
optometrists across the UK before introducing the COT that collected the data for this study.  
Finally, the study aims are outlined together with an overview of the chapters that follow. 
1.2 Bayes in ophthalmic research 
The fascinating history of Bayes’ theorem has been the subject of a book written by Sharon Bertsch 
McGrayne and entitled “The theory that would not die. How Bayes’ rule cracked the Enigma code, 
hunted down Russian submarines & emerged triumphant from two centuries of controversy” (2).  In 
the context of optometry, Bayes can be used to calculate the probability of an eye condition being 
present from its prevalence and any new evidence that arises from diagnostic tests.  
Table 1.1 provides a chronological list of studies in the field of ophthalmic research, outside that of 
COAG, which have applied Bayesian statistical analyses. 
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Year Brief description of topic studied 
1978 Computer assisted diagnosis in ophthalmology (3) 
1988 Post-operative refraction following cataract surgery (4) 
1992 Visual outcomes in diabetics with vitreous haemorrhage (5) 
1995 Assessment of retinal-neural function prior to laser treatment (6) 
1998 Lifetime prevalence of uveal melanoma (7) 
2003 Prediction of Snellen visual acuity (8) 
2003 Effect of steroids on aqueous humour outflow (9) 
2012 Effect of steroids on corneal ulcers (10) 
Table 1.1 Chronological list of studies in the field of ophthalmic research, outside the field of COAG, 
which has made use of Bayesian statistical analyses. 
At Aston University, Sagar investigated the accuracy of a diagnostic support system, based on 
Bayes, which was applied to making differential diagnoses in primary care optometry (1).  Her study 
explored how accuracy was influenced by circularity (testing a diagnostic support system using the 
same data used to build it), comorbidity (the coexistence of eye disease in one individual), 
prevalence and presentation variation (natural variations in symptoms and signs that occur with any 
eye condition).  She analysed 1422 of the optometric records collected in her practice. In a subset 
of her data, including 15 clinical tests and 10 eye conditions, her results indicated that Bayes could 
be applied with 100% accuracy as long as presentation variation was absent but fell to 94% when 
presentation variation existed.  Presentation variation is where a disease has a non-text book 
presentation for example not all patients with cataract will report reduced vision or glare.  This could 
confound the link between test findings and a specific diagnosis thus reducing accuracy (1).  
Surprisingly, circularity only artificially elevated accuracy by 0.5%. Sagar also trialled Chi-square 
filtering which removed weak associations between diagnostic tests and eye conditions but only 
increased accuracy by 0.4%.  When her analyses were extended to 105 clinical tests and 35 eye 
conditions, accuracy dropped to 72% and this fall in accuracy was most noticeable when prevalence 
was low and both comorbidity and presentation variation was high.  The largest contributor to the 
fall in accuracy was, however, considered to be that some eye conditions lacked strong diagnostic 
signs.  An important feature of her study was that only positive clinical test findings were recorded. 
17 
These positive clinical test findings could also have contributed to the reduction in accuracy and so 
her findings led to the notion that higher levels of accuracy could be achieved if both positive and 
negative test findings were recorded in clinical tests that belonged to a well-developed SOP. 
1.3 Bayes in glaucoma research 
Bayes has been used in glaucoma research.  In visual field research Bayes has been used 
extensively, linking structural and functional loss in glaucoma, developing visual field algorithms, 
software to detect glaucomatous field loss and assist clinicians determining progression in patients 
with glaucoma.  Table 1.2 lists these studies in chronological order.  However, none of these studies 
have considered the use of Bayes for clinical decision support in relation to the referral refinement 
of COAG. 
Year Brief description of the purpose of the study 
1994 Test strategies for detecting colour vision defects in patients with glaucoma 
(11) 
1997 Development of new SITA algorithms (12) 
2000 Determination of patient compliance in glaucoma cases (13) 
2003 
Development of a rapid threshold algorithm for short wavelength perimetry 
(14) 
2005 Investigation of visual field deterioration (15) 
2007 Classification of glaucoma from fundus photographs (16) 
2007 Prediction of night time intraocular pressure peaks (17) 
2008 Classification of glaucoma from structural and functional measurements (18) 
2009 Evaluation of quality of life and priorities in people with glaucoma (19) 
2009 Linkage of retinal structure and visual function in glaucoma (20) 
2011 Detection of progression from structural and functional measurements (21) 
2012 
Machine learning classifiers and optical coherence tomography in glaucoma 
(22) 
2013 Detection of progression from Heidelberg Retina Tomograph images (23) 
2013 Prediction of the prevalence of glaucoma in Asia (24) 
2013 
Detection of progressing glaucoma from retinal nerve fibre layer thickness 
(25)  
2015 Detection of glaucomatous progression (26, 27) 
2016 Effect of cataract surgery on intraocular pressure in glaucoma (27) 
Table 1.2 Chronological list of glaucoma studies that have involved the use of Bayes’ theorem. 
18 
1.4 Bayes in the present study 
Bayes was applied in the present study.  The assumption is that all diagnostic tests, carried out for 
the purpose of detecting COAG, are independent of each other (28).  In reality  this is not always 
the case.  However, Bayes in previous studies has been shown to render high levels of accuracy 
even when clinical tests are inter-dependent (1, 29).  The data within this study was highly 
structured with a sophisticated SOP so despite tests not being independent high levels of accuracy 
were anticipated. 
1.4.1 Diagnostic matrices 
Bayes can be applied to a single diagnostic test in relation to a single diagnosis or diagnostic 
outcome by using the diagnostic matrix shown in Figure 1.1 (30).  The figure shows a screenshot of 
the CatMaker program adopted by the Oxford Centre for Evidence Based Medicine 
(http://www.cebm.net/catmaker-ebm-calculators/) at the time of the present study.  CatMaker 
simplified the application of naïve Bayes by practitioners who may have limited knowledge of 
statistics.  Sagar applied the formulae shown in Figure 1.1 for her research (1). Cat Maker has been 
included to demonstrate how Bayes probabilities may be calculated .The present study used these 
formulae, however Cat Maker was not used to analyse the data in this study (see section 1.4.3). 
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Figure 1.1. Screen shot of the CatMaker program currently adopted by the Oxford Centre of 
Evidence Based Medicine. Naïve Bayes’ theorem is applied to a single diagnostic test in relation to 
a single diagnosis or diagnostic outcome. In this case, the diagnostic test is an intraocular pressure 
reading of >21 mm Hg and the diagnosis outcome is suspected COAG. The formulae shown were 
those used in the present study. 
Figure 1.1 shows a 2 x 2 decision matrix made up of cells a (true positives i.e. 6 cases with raised 
intraocular pressure and suspected COAG), b (false positives i.e. 11 cases with raised intraocular 
pressure did not have suspected COAG), c (false negatives i.e. 5 cases without raised intraocular 
pressure but with suspected COAG) and d (true negatives i.e. 1239 cases without raised intraocular 
pressure or suspected COAG).  Sagar’s data was extracted by the author from Sagar’s DOptom 
thesis (1).  Figure 1.1 shows calculations involved in the application naïve Bayes.  The first of these 
is the sensitivity (the probability of raised intraocular pressure if COAG is suspected) and specificity 
(the probability of normal intraocular pressure if COAG is not suspected).  In this case the sensitivity 
and specificity, expressed as a percentage, is 55% and 99%, respectively.   
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The problem with these values is that they say more about the probability of a test result if an eye 
condition is present or absent than the probability of having an eye condition if there is a positive or 
negative test result; the latter being what is required from the application of naïve Bayes theorem. 
Positive and negative likelihood ratios (LR) are calculated as an intermediate step towards getting 
the required answer.  It can be seen that likelihood ratios are derived from sensitivity and specificity 
and are the ratio of the probability of the diagnostic test being right over the probability of it being 
wrong when the test result is either positive or negative.  These ratios are used to raise or lower the 
post-test odds of a disorder being present.  It follows that if these ratios have a value of 1 then the 
test is of no diagnostic value at all (31-33).  On the other hand, a very high positive likelihood ratio 
indicates a diagnostically useful test because it dramatically elevates the post-test odds of an eye 
condition being present when the test result is positive.  A negative likelihood ratio close to zero also 
indicates a diagnostically useful test as it dramatically reduces the post-test odds that an eye 
condition is present when the test result is negative.  Figure 1.1 shows positive and negative 
likelihood ratios of 62 and 0.46, respectively.  
Note that the equation for negative likelihood ratio has been turned upside down so that it indicates 
the alteration to the post-test odds of suspected COAG rather than COAG not suspected.  In other 
words, a positive test result raises the post-test odds of referral by 62 times while a negative test 
result reduces the post-test odds of referral by 0.46 times.  The treatment of the negative likelihood 
ratio is very useful when multiple test outcomes are being considered (34, 35), as was the case in 
the present study.  This is because several positive and negative likelihood ratios could be 
combined into a single likelihood ratio by taking their product.  This would not have been possible 
had the negative likelihood ratios not have been turned upside down.  It is worth pointing out here 
that Sagar (1) only used positive likelihood ratios in her study as she only recorded positive test 
outcomes (see section 2.1). 
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According to Bayes, the post-test odds of an eye condition being present or absent is calculated by 
multiplying the pre-test odds (which is equal to the pre-test probability / [pre-test probability – 1] and 
is also known as the prior odds) by the appropriate likelihood ratio (i.e. positive or negative 
likelihood ratio depending on the test result).  The post-test probability is simply derived from the 
post-test odds (post-test probability = post-test odds / [1 + post-test odds]).  The method of 
generating the post-test probability is very useful when multiple test outcomes are being considered 
as it is derived from the pre-test odds multiplied by the product of all likelihood ratios from all tests 
carried out.   
Figure 1.1, however, shows an alternative way of calculating post-test probability; use of positive 
(PPV) and negative predictive values (NPV) (36, 37).  These predictive values are equal to the post-
test probability.  They were not used in the present study but are included here for the sake of 
completion.  The equation used to calculate the negative predictive value shown in Figure 1.1 was 
not turned upside down (as was the case for the equation used to calculate the negative likelihood 
ratio).  Nevertheless, this is effectively achieved by subtracting the negative predictive value shown 
from 100.  Expressed as a percentage, the predictive values show that a positive test result raises 
the probability of suspected COAG from 1% (the pre-test probability) to 35% while a negative test 
result lowers the probability of referral to 0% (100 – 100%). 
The data shown in Figure 1.1 can be used to make a well-known observation about screening for 
rare conditions (38).  The prevalence of suspected COAG was only 1%, making it relatively rare. 
What if referral for suspected COAG was purely based on intraocular pressure of greater than 21 
mmHg which had, in this case, a sensitivity of 55% and a specificity of 99%? Figure 1 shows that 17 
(cells a + b in the diagnostic matrix) referrals will have been made of which 65% (11 referrals, cell b 
in the diagnostic matrix) will have been false positives.  This would lead to significant unnecessary 
burden on the Hospital Eye Service (HES) (see section 1.7.2).   
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1.4.2 Laplacian correction 
The diagnostic matrix shown in Figure 1.1 lacked cells with zero counts.  Sagar, however, noted 
that these frequently occurred and complicated the application of Bayes to her clinical dataset (1).  
The biggest problem arose if zero counts gave rise to likelihood ratios of zero.  Recall from section 
1.4.1 that, when using multiple tests to determine the probability of a diagnosis or diagnostic 
outcome, several positive and negative likelihood ratios could be combined into a single likelihood 
ratio by taking their product.  If just one of those likelihood ratios was zero, then the combined 
product would also be zero regardless of whether the likelihood ratios for the other tests were very 
large effectively ruling out the diagnosis or diagnostic test outcome.  The solution to the problem is 
to make a Laplacian correction (35).  Usually this involves adding 1 to the counts in each cell of the 
diagnostic matrix which eliminates cells with zero counts together with the possibility of likelihood 
ratios of zero (35).  The philosophical rationale for the Laplacian correction is that a likelihood ratio 
of zero absolutely rules out a diagnosis or diagnostic outcome when, in reality, no statistical model 
is perfect enough to do this.  The Laplacian correction effectively remedies this at the cost of small 
artificial alterations to the calculated likelihood ratios.  Sagar used a Laplacian correction of 0.001 
(1) to ensure that this caused minimal alterations to likelihood ratios calculated for rare test
outcomes or eye conditions.  The same Laplacian correction was adopted in the present study. 
1.4.3 Generation of Bayes learning curves 
Sagar created Microsoft Excel spreadsheets to apply Bayes to multiple tests and diagnoses (1).  
These dramatically sped up the process of carrying out the calculations described in Figure 1.1 for 
the large number of diagnostic matrices relating to each of her test / diagnosis combinations (105 
tests x 35 diagnoses = 3675 diagnostic matrices).  The spreadsheets allowed her to calculate the 
accuracy with which this form of artificial intelligence could match her own diagnoses (1). 
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While use of spreadsheets was sufficient for her purposes they did not readily lend themselves to 
the generation of learning curves that show the speed with which maximum accuracy is achieved 
when applying Bayes.  Fortunately, Aston Eyetech Limited (AEL), a spin out company of Aston 
University, had developed a computer program (the AEL Bayes application) that applied Sagar’s 
computing scheme to measure accuracy (1) and could construct Bayes learning curves.  The 
software adopted a Laplacian correction of 0.001 and was used in the present study.  
The Aston Bayes application could divide any clinical dataset into 20 approximately equal cohorts. 
It learned from the first cohort of data.  
Learning consisted of: 
(a) Calculating pre-test odds for each of the diagnostic outcomes;
(b) Generating diagnostic matrices for every combination of clinical test and diagnostic
outcome; 
(c) Calculating the sensitivity, specificity and likelihood ratios for every diagnostic matrix.
System accuracy was then calculated by: 
(a) Applying Bayes’ to all remaining cases, those not used for learning, by multiplying the
pre-test odds of each diagnostic outcome by the corresponding positive or negative 
likelihood ratio for every clinical test finding, in order to determine post-test probabilities for 
all diagnostic outcomes; 
(b) Selecting, for each case, the diagnostic outcome with the highest post-test probability as
the chosen diagnostic outcome; 
(c) Comparing, for each case, the chosen diagnostic outcome with the actual one made by
the practitioner and; 
(d) Calculating the percentage of cases for which the chosen and actual diagnostic outcome
matched.   
The process was repeated on the remaining cohorts and continued until all cohorts had been used 
for learning.   
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System accuracy was then plotted as a function of the number of records used for learning.  The 
resulting learning curve could show how many cases were needed before the graph reached an 
asymptote representing maximum system accuracy. 
Figure 1.2 shows learning curves plotted using the AEL Bayes application.  The author ran  analysis 
on 1261 of Sagar’s eye examination records (1).  Sagar’s original dataset included 1422 records 
and application of naïve Bayes theorem to this data gave rise to an accuracy of 72% (see section 
1.2).  Subsequent detailed analyses of the dataset by Malcolm Maciver, Edward Kundzikz, Arti 
Patel, Komail Ladha (undergraduates, working towards their third year dissertations on the 
optometry degree course), revealed that the diagnoses lacked supporting signs in 161 records.  
This was considered to be due to the lack of an SOP for recording clinical findings and almost 
certainly reduced accuracy. 
Sagar was not able to generate a learning curve but Figure 1.2 shows that after removal of 161 
aberrant records by the author, the AEL Bayes application rapidly learned and levelled off at an 
accuracy of 97% ‘by record’ and 98% ‘by eye condition’.  Accuracy ‘by record’ represented the 
percentage of times that the AEL Bayes application identified all eye conditions manifest in each 
record; comorbidity was common.  Accuracy ‘by condition’ represented the percentage of times a 
specified eye condition was identified in every record, regardless of whether or not other comorbid 
eye conditions were identified. 
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Figure1.2. Screen shot of Bayes learning curves generated by the AEL Bayes Application. The 
analysis was carried out on 1261 records collected by Sagar (1) which included 105 diagnostic test 
findings and 27 suspected eye conditions. Learning curves were analysed ‘by record’ (yellow line) 
and ‘by eye condition’ (blue line). 
Recall that Sagar only recorded positive test results (1).  A major assumption made in the author’s 
re-analysis of her data, shown in Figure 1.2, was that the lack of a positive test result represented a 
negative test result.  This allowed both positive and negative likelihood ratios to be used.  The lack 
of a positive test result could actually have meant that a test had not been performed at all.   
The promising levels of accuracy shown in Figure 1.2 might, therefore, be fictitious, which reinforced 
the need for the present study in which the speed of learning and the accuracy level achieved could 
be re-examined in clinical data collected using an SOP in which positive and negative test findings 
were recorded.   
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1.4.4 Use of likelihood ratios for multiple cut-off points 
Figure 1.1 considered a single cut-off point of >21 mmHg for intraocular pressure as a means of 
detecting COAG.  While receiver operator curves can be used to identify an optimum single cut-off 
point (39, 40), Parikh’s research group recommended the use of multiple cut-off points in order to 
individualise clinical decisions (31).  Indeed, it seemed intuitively obvious to the author that all 
intraocular pressure values signal some risk of POAG.  Why not calculate likelihood ratios for 
multiple cut-off points?  Application of Bayes would then involve selecting the likelihood ratio that 
matched an individual’s intraocular pressure.  Although Sagar had not used multiple cut-off points in 
her study, she did recommend that future research might consider this for parameters such as age, 
intraocular pressure and cup-to-disc ratios (1).  For this reason, multiple cut-off points were adopted 
in the present study.  The author initially considered using multiple cut-off points in the form of, for 
example, >21mmHg, >25mmHg, >30mmHg, and so on, for measurements of intraocular pressure.  
However, objections were raised against this approach by one of Aston’s Bayes experts (Professor 
Ian Nabney, Centenary Professor of the System Analytics Research Institute, SARI).  These 
objections were based on the fact that use of these cut-off points would further violate the 
assumption of Bayes, that test results were independent (see section 1.4).  For example, an 
individual pressure reading of 32mmHg would actually fall into all three groups mentioned above.  
On the other hand, the expert advisor had no objection to using multiple mutually exclusive 
intraocular pressure categories, such as 21 to 24mmHg, 25 to 29mmHg, 30 to 35mmHg, and so on, 
as now a pressure of 32mmHg would only fall into one group.  The author adopted this alternative 
form of multiple cut-off point (see chapter 3). 
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1.5 Glaucoma  
1.5.1 Prevalence of glaucoma 
Population studies had shown that the prevalence of glaucoma for all age groups ranged from 0.8% 
(41) to 7% (42).  Table 1.3 summarises the prevalence of glaucoma in the major epidemiological 
studies.   
Study Prevalence  
Rotterdam study (41)  1990-1993 0.8% 
PVER study (43)  1999-2000   1.8% 
Melbourne VIP (44)   1991-1998 1.8% 
Beaver Dam study (45)  1988-1990 2.1% 
Baltimore eye survey (46)  1985-1988 2.5% 
Blue Mountains study (47)   1992-1994 2.8% 
Kongwa Eye Project (48)   1996 3.0% 
Barbados study (42)   1988-1992 7.0% 
 
Table 1.3 Prevalence of glaucoma estimated from major epidemiological studies. The studies have 
been arranged in order of increasing prevalence to show the range of values found. 
 
The global estimate of the prevalence of glaucoma for people of 40 to 80 years is 3.5% (49).  
Declining fertility rates and reducing mortality rates mean that there is an ever increasing number of 
people in this age group (50), making glaucoma a growing major public health concern. 
Due to the worlds increasing population by 2020 it is expected that 79.6 million people worldwide 
will have glaucoma (51) and this will rise to 111.8 million by 2040 (49). Glaucoma is the second 
leading cause of blindness in the world (51).  Nearly three quarters of these individuals will have 
open angle glaucoma resulting in bilateral blindness for 5.9 million people (51). 
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In the UK, COAG affects 2% of the population over 40 rising to 10% in those over 75 years of age 
(52).  The number of individuals with open angle glaucoma in England is almost half a million (52).  
Every year there is estimated to be 11,054 new cases of POAG in the UK for people between 40-70 
years of age (53), 9263 cases in England alone (53).  Approximately 20% of referrals to the Hospital 
Eye Service (HES) in the UK are due to glaucoma (54).  Individuals with glaucoma will require 
lifelong monitoring for signs of progression and disease control as any sight lost is permanent and 
cannot be restored (52).  The yearly cost of monitoring these patients is estimated at £22,469,000 
(52). 
Glaucoma is the third most common cause responsible for severely sight impaired (SSI) 
registrations and second most common cause for sight impaired (SI) registrations in England and 
Wales (55).  Figure 1.3 shows the causes of SSI registrations in the UK from April 1999 to March 
2000.  Figure 1.4 shows the causes of SI registrations in the UK over the same period. 
 
Figure 1.3 Causes of certifications for Severely Sight Impaired Registrations in England and Wales 
(April 1999 to March 2000). Adapted from data by Bunce and Wormald (55). 
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Figure 1.4 Causes of certifications for Sight Impaired Registrations in England and Wales (April 
1999 to March 2000). Adapted from data by Bunce and Wormald (55). 
 
1.5.2 Classification of glaucoma 
Glaucoma is usually classified by either the aetiology or the mechanism of damage.  Glaucoma may 
be primary when no other disease is implicated or secondary where it is due to another detectable 
comorbidity.  Glaucoma may be further divided clinically into open and closed angle on the basis of 
gonioscopic examination of the drainage angles.  The exact mechanism for variations in 
susceptibility and patterns of damage seen in glaucoma is not known although the pathogenesis is 
likely to be multifactorial (56). 
1.5.3 Chronic Open Angle Glaucoma (COAG) 
1.5.3.1 Clinical features of COAG 
The present study was primarily concerned with the application of Bayes to the referral refinement 
of COAG.  For this reason, COAG is described in more detail than other forms of glaucoma, which 
are included later for the sake of completion.  Figure 1.5 shows a normal optic nerve head with a 
healthy neuroretinal rim. 
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Figure 1.5 Colour photograph of an optic nerve with healthy neuroretinal rim tissue (taken by the 
author). 
 
Chronic Open Angle Glaucoma is a progressive chronic optic neuropathy with characteristic 
changes at the optic nerve head and in the retinal nerve fibre layer which result from a loss of 
ganglion cells and are associated with progressive visual field loss.  Figure 1.6 shows a wedge 
defect resulting from localised loss of the retinal nerve fibre layer in a person with COAG.   
 
Figure 1.6 Red free photograph of a wedge defect of the Retinal Nerve Fibre layer seen in the right 
eye of a person with COAG (taken by the author). 
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Chronic Open Angle Glaucoma exhibits increased cupping of the optic nerve head which is often 
termed Glaucomatous Optic Neuropathy (GON). Figure 1.7 shows an optic nerve head exhibiting 
GON.   
 
Figure 1.7 Colour photograph showing loss of neuroretinal rim tissue in the same right optic nerve 
head as shown in Figure 1.6 (taken by the author).  
 
Glaucomatous damage starts with thinning of the neuroretinal rim of the optic nerve head 
progressing to advanced cupping which is associated with visual field defect loss.  The earliest 
glaucomatous visual field loss is often in the paracentral area (57) and progresses to a nasal step, 
arcuate and advanced visual field loss.  Figure 1.8 shows a superior arcuate visual field loss as a 
result of COAG.  
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Figure 1.8. Visual field plot showing superior arcuate visual field loss in the same right eye as 
shown in Figures 1.6 and 1.7 (recorded by the author). 
 
Often only a temporal island of vision remains in advanced visual field loss rendering the patient 
almost totally blind.  Approximately  40-50% of the retinal nerve fibres need to be lost before there is 
an impact on visual function (58).  COAG is responsible for 50% of blindness associated with 
glaucoma (53) and is often but not always associated with raised intraocular pressure (IOP) (41) 
due to resistance of aqueous outflow in the trabecular meshwork.   
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Primary glaucomas make up 80% of the glaucoma sufferers in the world (59).  Open angle 
glaucoma makes up two thirds of the glaucoma population worldwide (51).  In the UK it is estimated 
that 67% of open angle glaucoma goes undetected (53) because it remains asymptomatic until it 
becomes advanced. 
1.5.3.2 Risk Factors for COAG 
Increasing age is the single most important risk factor for COAG.  Other risk factors include raised 
intraocular pressure (IOP), central corneal thickness and family history.  These factors and their 
inclusion in the present study are explained further in chapter 2. 
1.5.3.3 Pathophysiology of COAG 
COAG is a bilateral asymmetrical condition at diagnosis and throughout its clinical course (60).  It is 
known that retinal ganglion cell axons undergo apoptosis but the exact cause of this is not 
completely clear (61).  Three main theories emerge from the literature; mechanical, vascular and 
biomechanical. 
1.5.3.3.1 Mechanical Theory 
The mechanical theory proposes that increased IOP is caused by obstruction and resistance of the 
aqueous humour outflow at the level of the trabecular meshwork.  The resultant increased pressure 
imparts mechanical stress causing stretching of the lamina cribrosa.  The ganglion cell axons pass 
through the lamina cribrosa so that they are damaged and lost directly because of this stress (62).  
Elasticity of the lamina cribrosa connective tissue reduces with age so any deformation will cause 
pressure on the nerve axons passing through it (63).  The thickness of the lamina cribrosa 
increases with age which may also contribute to pressure on nerve axons (64). 
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1.5.3.3.2 Vascular Theory 
The vascular theory relates to reduced or insufficient ocular blood flow.  Reduced ocular blood flow 
at the optic nerve head may result from faulty autoregulation, unstable ocular perfusion, local 
vasospasm, and high blood viscosity; all of which lead to ischemia and hypoxia (65).  Raised IOP 
may reduce ocular blood flow to the optic nerve by compression of the capillaries causing localised 
ischemic damage (66).  In support of this theory, ocular blood flow tends to be reduced in glaucoma 
(67-69). 
1.5.3.3.3 Biochemical Theory 
The biochemical theory suggests that COAG results from autoimmune damage.  Mechanical stress 
is thought to cause the release of neurotoxins such as nitric oxide from retinal glial cells.  Exposure 
to high levels of nitric oxide may damage the axons of the retinal ganglion cells (70).  Mitochondrial 
dysfunction is often present in glaucomatous eyes and it is thought that the resulting oxidative 
stress may also cause glaucoma (71).  The exact mechanism by which oxidative stress causes 
glaucoma is not yet fully understood.  
1.5.4 Normal tension glaucoma 
Normal tension glaucoma (NTG) or low tension glaucoma (LTG) occurs with normal IOP; less than 
21 mmHg (72).  There is current disagreement in the literature on whether NTG is a separate entity 
or a variant of COAG (73).  NTG may also be described as a condition of exclusion where the optic 
disc damage and subsequent field loss cannot be attributed to any other pathological condition (74).  
NTG was once considered quite rare but several recent studies have revealed that it may account 
for between 20-40% of all open angle glaucoma (75). 
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Patients who suffer from vascular dysregulation syndrome tend to have low blood pressure 
(systemic hypotension) (76).  They suffer from cold extremities of the hands and feet and conditions 
such as Raynauds syndrome and migraines (77).  These patients have a higher prevalence of NTG 
which seems to be related to their ocular blood flow.  People with vascular dysregulation syndrome 
tend to have stiffer retinal blood vessels with a higher spatial irregularity so that vasodilatation is 
reduced, leading to reduced ocular perfusion of the optic nerve head (77, 78).  The reduced 
perfusion to the optic nerve head is believed to be the cause of NTG. 
1.5.5 Ocular hypertension 
Ocular Hypertension (OHT) is defined as consistently or recurrently elevated IOP of greater than 
21mmHg in the absence of optic nerve damage, visual field loss or closed aqueous drainage angles 
(52).  In England it is estimated that one million people have OHT, 3-5 % of the people aged over 40 
years (52).  OHT can progress to COAG (79).  The risk of conversion from OHT to COAG 
decreased from 9.5% to 4.4% after 5 years with ocular hypotensive medication (79).  
1.6 NICE guideline CG85 
The National Health Service (NHS) receives guidance from NICE that is gathered by established 
literature search methods that respect a hierarchy of research evidence (80-82).  In 2009, NICE 
published guideline CG85 for the diagnosis, management and treatment of COAG and OHT (52). 
The sections that follow (1.6.1 to 1.6.8) cover those aspects of the NICE guidelines that inform the 
present study (52). 
1.6.1 Goldmann applanation tonometry 
Goldmann applanation tonometry (GAT) is considered by NICE to be the reference standard for 
measuring IOP (52).  Although non-contact tonometry (NCT) was less costly, experts were of the 
opinion that GAT was more accurate and that its use for detecting COAG and OHT would save 
more money by reducing inappropriate treatment (83).   
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1.6.2 Central corneal thickness 
Central Corneal Thickness (CCT) is a risk factor for conversion of OHT to COAG (79, 84, 85).  
While NICE recommended measurement of CCT, no specific method was specified (52). 
1.6.3 Anterior chamber angle assessment  
Despite being more costly than alternative techniques, gonioscopy was considered by NICE to be 
the reference standard for assessment of the anterior chamber angle (52).  The clinical evidence 
reviewed indicated that gonioscopy revealed more detailed information than van Herick’s test (86), 
the flashlight test (87), the scanning Peripheral Anterior Chamber Depth analyser (86) and non-
contact anterior segment optical coherence tomography (88).  However, NICE recommended that 
van Herick’s test was suitable if gonioscopy was not possible due to physical or mental health 
concerns relating to the patient (52). 
1.6.4 Visual field assessment 
The SITA (Swedish interactive thresholding algorithm)  24-2 testing strategy was considered by 
NICE to be the reference standard for visual field assessment but no perimeter was specified (52).  
Literature comparing SITA 24-2 with other strategies were lacking but NICE recommended that a 
threshold technique, such as SITA, was used for any patient suspected of having glaucoma (52). 
1.6.5 Optic nerve head assessment  
Dilated stereoscopic evaluation with a slit lamp biomicroscope by a trained clinician was considered 
by NICE as the reference standard for optic nerve head assessment (ONHA)  (52).   
Slit lamp biomicroscopy was less expensive than alternative techniques which included Laser 
Polarimetry, optical coherence tomography and the Heidelberg Retina Tomograph (52).  NICE 
recommended slit lamp biomicroscopy on its own as combining it with stereoscopic optic disc 
photography increased the cost (52).   
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Although NICE recognized that a stereoscopic optic disc photograph taken at the first visit was a 
useful means of establishing any progression of COAG or conversion of OHT to COAG at 
subsequent visits, the NICE guidelines were written when this technology was not commonly 
available in clinical practice.    
1.6.6 Training for referral refinement 
1.6.6.1 Requirements of NICE 
The NICE guidelines stated that clinicians involved in referral refinement should: 
a. Have a specialist qualification or be working under the supervision of a consultant 
ophthalmologist. 
b. Have enough experience to perform and interpret the relevant clinical tests, such as those 
described in sections 1.6.1 to 1.6.5 above. 
While these guidelines allowed clinicians with a specialist qualification to carry out referral 
refinement without the need to be supervised by a consultant ophthalmologist (as was the case for 
the COT optometrists that took part in the present study), the specialist qualifications were not 
specified.   
1.6.6.2 Development of specialist qualifications for optometrists 
Over the past 20 years optometrists have been increasingly involved not only in case detection of 
OHT and COAG but in diagnosis, monitoring and treatment of these conditions (89).  
To help develop and expand the role of optometrists in this area, specialist qualifications have been 
developed by the College of Optometrists (COO).   
In 1999, the COO glaucoma certificate A was available followed in 2004 by certificate B (90).  The 
certificates were developed by both specialist ophthalmologists and optometrists working in the field 
of glaucoma.   
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The aim of the certificates was to allow optometrists to further develop skills, experience and 
understanding of glaucoma (90).  Part A was designed for optometrists working in a glaucoma 
referral refinement scheme while Part B was designed to allow optometrists to work independently 
in the management of glaucoma and OHT (90).  Candidates who passed part A were awarded the 
Diploma in Ocular Conditions (Dip Oc).  Those who passed Parts A and B were awarded the 
Diploma in Glaucoma (Dip Glauc).  Due to lack of demand, the COO now only offers Part B for 
those candidates still needing to complete their examinations (91). 
These qualifications were replaced by three new qualifications in glaucoma: the Professional 
Certificate in Glaucoma (Prof Cert Glauc), the Professional Higher Certificate in Glaucoma (Higher 
Cert Glauc) and the new Diploma in Glaucoma (Dip Glauc).  The Professional Certificate was 
developed for optometrists to participate in formal referral refinement and OHT/suspect COAG 
monitoring schemes (92).  The Professional Higher Certificate prepared optometrists to participate 
in community or hospital-based schemes involving the diagnosis of OHT and preliminary diagnosis 
of COAG (92).  The Diploma was designed for optometrists to participate in community or hospital-
based schemes for the management of patients with established COAG (92).  To obtain the Higher 
Certificate, 150 patients of varying degrees of clinical complexity needed to be examined in a 
clinical placement under an ophthalmologist mentor.  For the Diploma a further 250 cases needed 
to be seen (90).   
The higher qualifications in glaucoma were available at several UK institutions including University 
College London and Cardiff University.  The COO provided training institutions with guidance.  
These providers also needed accreditation by the COO (93).  The rigorous accreditation process 
and clinical placement ensured that optometrists awarded these higher qualifications had the 
necessary skills, expertise and experience in the field of glaucoma that was required by NICE.   
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1.6.7 Consultant ophthalmologists are responsible for the final management plan 
An evaluation was carried out by NICE of several studies comparing a range of healthcare 
professionals in the monitoring of patients with OHT and COAG (94-98).  These healthcare 
professionals included optometrists and ophthalmologists who were non-specialists and specialists. 
Agreement between optometrists and ophthalmologists varied from fair to substantial, depending 
upon the degree of specialisation.  From this evidence, NICE concluded that the consequence of 
either failing to identify COAG or incorrect diagnosis may lead to irreversible blindness and visual 
disability.  Therefore, COAG had to be diagnosed by a consultant ophthalmologist who could form 
the clinical management plan and reduce this risk to a minimum (52).  
1.6.8 Recommended treatment plan 
The treatment plan recommended by NICE for OHT and suspected COAG (Table 1.4) was based 
on the risk for conversion of OHT to COAG.  It acknowledged the relationship between IOP and 
CCT (see section 1.6.2) and shows how the decision to treat or not depends on IOP, CCT and age. 
Table 1.4 will be referred to again in chapter two when multiple cut-off points for clinical tests is 
revisited.   
As the study described in this thesis was concerned with referral refinement, further treatment and 
follow-up options recommended by NICE are not covered. 
IOP CCT <555 CCT 555-590   CCT>590 
>21mmHg to 25mmHg treat with PGA until 65  no treatment no treatment 
>25mmHg to 32mmHg treat with PGA until 80 treat with BB until 60 no treatment 
>32mmHg  PGA  PGA  PGA 
Table 1.4 Treatment plan recommended by NICE (52).  Note that the decision whether or not to 
treat with BB (beta-blockers) or PGA (prostaglandin analogue) is dependent on IOP, CCT and age. 
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1.7 Referral Refinement 
Glaucoma sufferers are often unaware of their progressive loss of visual field until late in the 
disease process when it affects the central vision (99).  Late presentation is a major risk factor for 
blindness attributed to glaucoma (100).  Early detection of the disease is therefore vital.   
Currently there is no formal screening programme for COAG or OHT.  There is a lack of high quality 
research evidence to support formal screening (101) and it is not considered to be cost effective 
(53, 102), though screening patients in high risk groups, such as those of black ethnic origin, may 
be more beneficial (53, 100).  The most recent policy review by the UK National screening 
committee reported in 2016 and confirmed that formal screening for glaucoma is still not currently 
recommended (103).  A further review is due in 2018/19.   
Because of the absence of a formal screening programme, most cases of COAG and OHT are 
found opportunistically by community optometrists when patients attend for routine eye 
examinations (104).  Patients suspected of having OHT or COAG are usually referred into the HES 
for formal diagnosis, treatment and monitoring (105). 
Following publication of NICE guideline CG85 (see section 1.6), advice was issued by the COO and 
Association of Optometrists (AOP) stating that, in the absence of funding for repeat IOP 
measurements using GAT, optometrists had no choice other than to refer a patient who had raised 
IOP (indicating OHT) using whatever tonometer they chose.   Furthermore, they advised that failure 
to refer a case with suspected OHT may be considered unprofessional (106). 
In response to this advice, referrals to the HES for suspected COAG and OHT doubled (107).  A 
web-based questionnaire was sent to 9386 optometrists on the COO mailing list asking about 
referral behaviour.  Extrapolation of the results to reflect all optometrists on the General Optical 
Council (GOC) register revealed that the advice given had resulted in 540,000 extra referrals to the 
HES per year (108).   
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Schemes started to develop in different parts of the country (38, 105, 111-114).  These developed 
local agreed protocols and usually involved multidisciplinary teams.  Some schemes were simply 
repeat measures where practitioners repeated IOP measurements with GAT or carried out repeated 
visual field tests.  Some utilised specialist optometrists for enhanced case finding.  Others, including 
COT, involved specialist optometrists in true Glaucoma Referral Refinement (GRR) where the 
undertaking of tests are sufficient to diagnose OHT and suspect COAG (115, 116).  In addition to 
reducing false-positive referrals to the HES by 35-77% (Table 1.5), these also reported cost savings 
of up to £117 per patient (113) and reduced waiting times (38).  
Scheme Reduction of referrals (%) 
Huntington (114) 35 
Manchester (38)  40 
Carmarthenshire (113) 53 
Nottingham (111) 54 
RCAS (105) 71 
EGRM (105) 76 
Stockport, Tameside, Glossop (112) 77 
 
Table 1.5 Reduction in false-positive referrals to the HES due to various schemes operating across 
the UK. Studies are shown in ascending order of reduction in referrals. Key: RCAS = Refinement by 
the Community Team after Clinical Assessment Scheme, EGRM = Enhanced Glaucoma Repeat 
Measurement scheme. 
 
One of the studies indicated that a scheme involving repeat measurements by non-specialist 
optometrists was more cost-effective and reduced false positives just as effectively as a scheme 
involving a team of specialist optometrists (105). 
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1.8 Community Ophthalmology Team 
1.8.1 History and regional coverage 
The COT was set up in 2006 in conjunction with consultant ophthalmologists from the Maidstone and 
Tunbridge Wells NHS Trust and the West Kent Primary Care Trust. 
The COT allows optometrists the opportunity to extend their role in providing a range of ophthalmology 
services in their local community.  It is a multidisciplinary team which uses the different skills of its 
members to enhance patient care.  The advantages of optometrists working so closely with the 
ophthalmologists is the development of excellent working relationships, continuing education and a 
mutual understanding of each other’s skill sets.    The benefit to the patient is that they are seen more 
quickly by the appropriate clinician.   Allowing the lower risk patients to be seen in the community by 
the COT facilitates more consultant ophthalmologist hospital clinic time for those patients deemed at 
greatest risk of sight loss due to glaucoma. 
On the 1st April 2013, Strategic Health Authorities and Primary Care Trusts were abolished by the 
government in favour of the NHS commissioning board (NHSCB) and Clinical Commissioning Groups 
(CCGs).  Following this change, the COT was commissioned in three CCGs:  
(i) West Kent - 463,000 residents and 62 general practitioner (GP) practices (117); 
(ii) Medway - 283,000 residents and 56 GP practices (118); 
(iii) Dartford, Gravesham and Swanley - 249,000 residents and 34 GP practices (119).      
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The commissioning of the COT across the 3 CCGs in Kent is unique within England and Wales and 
the COT continues to flourish. The CCGs and the Maidstone and Tunbridge Wells NHS Trust are 
looking at measures to expand the COT further with more glaucoma and medical retina patients being 
discharged into the community for management by the COT.  Recently the Clinical Council for Eye 
Health Commissioning has published a Community Ophthalmology Framework which is very similar 
to the COT and endorses its approach (120). 
1.8.2 Specialist accreditation and continued training 
The COT currently employs the services of 15 Optometrists and one GP.  The COT is mentored by 
Lead Consultant Ophthalmologist, Professor Ejaz Ansari.  All optometrists working in the COT receive 
training in hospital clinics and, after accreditation by Professor Ansari, are allowed use of the affix 
Optometrist with Special Interest in Ophthalmology (OPwSI).   
Accredited optometrists receive annual appraisal with Professor Ansari and are required to undertake 
any training facilitated by the commissioners.  The training is regularly repeated to ensure patient 
safety, continuity with the HES glaucoma service and compliance with NICE guidelines (see section 
1.6).  In addition, COT practitioners have direct access to advice from Consultant Ophthalmologists 
via telephone or NHS secure email regarding the management of any patient they are seeing on 
behalf of the COT. 
The author and two of his colleagues, Deacon Harle (DH) and Niall O’Kane (NOK), were all involved 
in clinical data collection for the study described in within the thesis.  All are Independent Prescribing 
(IP) optometrists.  The author also holds the Higher Cert Glauc and DH the Dip OC. 
1.8.3 Operating procedures 
All non-emergency ophthalmology referrals (excluding any patient under 16, for which there is a 
different pathway) by GPs, pharmacists and non-specialist community optometrists working in the 
three CCGs are sent to the Primary Care Booking Service (PCBS) in Maidstone.  
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Referrals are uploaded onto a secure NHS system by the PCBS staff.  Each month one of the 
members of the COT triages the referrals on a daily basis from this system and advises the PCBS 
whether the patient is suitable to be seen by a member of the COT or by their HES colleagues.  
Patients that can be seen safely in the COT are contacted by the PCBS and offered an 
appointment.  
Elements of the SOP used by the COT that have direct relevance to the present study include: 
i. Taking family history of glaucoma (FHG); 
ii. Gonioscopy to establish that the drainage angle is open;  
iii. GAT; 
iv. CCT by ultrasound pachymetry; 
v. Dilated stereoscopic ONHA with Volk lens to enable; 
a) Measurement of vertical optic disc size (VDS) with thin slit lamp beam directed onto the 
disc with the slit lamp graticule used to reduce height of beam until it corresponds with 
the size of the disc.  The VDS can then be read directly from the graticule and a 
correction factor applied if required; 
b) Estimation of the vertical cup-to-disc ratio (VCDR); 
vi. Visual field assessment using the Humphrey Visual Field Analyser SITA fast 24-2 strategy. 
More details about the ophthalmic instrumentation used by the three COT members who 
participated in the study and grouping of clinical data into multiple cut-off points are provided in 
Chapter 2. 
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The management options, of direct relevance to the study described in this thesis, following the 
COT appointment were as follows: 
i. Discharge(Dis); 
ii. Follow-up in the COT for suspected COAG(Fup); 
iii. Refer to the HES for COAG (Refer). 
1.9 Aim of the present study  
The aim of the study was to determine whether application of naïve Bayes to clinical data collected 
using the established SOP of the COT could accurately replicate clinical decisions relating to the 
referral and management of COAG made by three IP optometrists with a special interest in 
ophthalmology.  A major feature of this study was its adoption of likelihood ratios for multiple cut-off 
points (see section 1.4.4).  As three optometrists were involved, the opportunity also arose to study 
the consistency of system accuracy and speed of learning.  Likelihood ratios generated for each 
component of the SOP were also used to determine whether there was any redundancy; that is, 
could the SOP be further refined?   
As far as the author and his supervisory team were aware, this was the first investigation of naïve 
Bayes as a means of providing clinical decision support for refinement of referrals relating to 
suspected COAG.  As such, the scope of the study was believed to constitute a substantial and 
original contribution to knowledge in this field.  
 
 
 
 
 
 
 
46 
 
 
1.10 Summary and chapter outline 
 
Chapter 1 has outlined the background and aims of this study.  Chapter 2 provides a more detailed 
description of the ophthalmic instrumentation used by the three COT members who participated in 
this study and grouping of clinical data into multiple cut-off points.  A preliminary analysis of clinical 
data is described in Chapter 3.  Application of naïve Bayes is evaluated in Chapter 4 in terms of its 
accuracy, speed of learning, consistency and the presence of any redundancy.  Chapter 5 ends the 
thesis with a review of key findings, a critique and recommendations for further research. 
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Chapter 2: Methods 
2.1 Introduction 
The purpose of this study was to determine the accuracy of clinical decision support based on naïve 
Bayes when applied to a well-developed SOP.  The SOP, used by the author and two of his 
colleagues for referral refinement of COAG, was introduced in chapter 1 (see section 1.8.3).  
Chapter 2 describes the SOP in more detail.  The recommendation by Parikh’s research group to 
use likelihood ratios for multiple cut-off points was also introduced in chapter 1 (see section 1.4.4).  
Chapter 2 also provides a description of how the clinical data was grouped to enable use of multiple 
cut-off points.    
2.2 Ethics 
Approval was granted from the Life and Health Sciences Research Ethics Committee at Aston 
University (Project 495).  Ethical clearance was based on data collection being treated as a clinical 
audit.  Treating the study as an audit allowed collection of fully anonymised data without the consent 
of the individuals being examined, ensuring that all referral refinements carried out by the COT 
during the study period (see section 1.8.2) could be included.  Failure to consent would otherwise 
have distorted the prior odds (see section 1.4.1) upon which naïve Bayes depended. 
2.3 Data Collection 
Clinical data for this study represented all referrals for suspected COAG seen by the author (JG) 
and two of his colleagues (DH and NOK, see section 1.8.2) between 1st October 2014 and 1st 
October 2015.   
Patients referred or followed up for any other reason were excluded as were those unable to 
undertake visual fields for medical reasons such as dementia. 
A total of 1069 patients were examined and 63 cases were excluded for the reasons stated above 
which left 1006 cases; 451 from JG, 486 from DH and 69 from NOK.   
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Data was taken from the worst affected eye or, if there was no asymmetry in severity, from the right 
eye.  The sections that follow detail the clinical data and its grouping for the purpose of using 
likelihood ratios for multiple cut-off points (see section 1.4.4). 
2.3.1 Age 
Increasing age is a major risk factor for the development of COAG.  Table 2.1 shows the increased 
prevalence of COAG with age in some of the major epidemiological studies. 
Study  Age Range (years) Prevalence (%) 
Beaver Dam(45) 43-54 0.9 
Beaver Dam(45) over 75 5.0 
  
 
Barbados(42)  over 50 9.0 
Barbados (42) over 70 17.0 
  
 
Rotterdam(41) 55-59 0.3 
Rotterdam(41) 85-89 3.3 
  
 
Baltimore Whites (120) 40-49 0.9 
Baltimore Whites (120) over 80 2.2 
 
Table 2.1 Prevalence of COAG estimated from some major epidemiological studies. 
 
Table 2.2 shows how age was grouped in these studies compared to the present study. 
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Study Age Groups (years) 
Beaver Dam (45) 43-54, 55-64, 65-74, 75+ 
Blue Mountains(47) <60, 60-69, 70-79, 80+ 
Baltimore (46) 40-49, 50-59, 60-69, 70-79, 80+ 
LA Latino (121) 40-54,55-64,65-74,>75,>80 
Barbados(42) 40-49,50-59,60-69,>70 
Tanjong Pagar(122) 40-49,50-59,60-69,70-79 
Present study <40, 40-49, 50-59, 60-69, 70-79, 80+ 
 
Table 2.2 Age groups adopted in major epidemiological studies.  
2.3.2 Race  
Studies have shown that race influences the prevalence of COAG (Table 2.3).  The prevalence of 
COAG ranges from 0.8% in Caucasians to 8.8% in Afro Caribbeans.  The racial groups adopted in 
the present study were those shown in Table 2.3. 
Study Caucasian Asian Afro Caribbean African Hispanic Prevalence (%) 
Rotterdam(41)  X         0.8 
Melbourne VIP(44)  X         1.7 
Proyecto VER (123)               X  2.0 
Blue Mountains 
(47)  
X         2.0 
Mongolia(124)   X       2.1 
Liwan (125)   X       2.1 
Thailand (126)   X       2.3 
Southern India (127) 
 
X       2.6 
West of Ireland (128) X         2.8 
Chennai (129)   X       3.2 
Tanjong Pagar (122)   X       3.2 
Kongwa district (48)       X    4.2 
LA Latino study (121)         X 4.7 
Barbados (42)     X     6.7 
Ghanaian (130)       X   7.7 
St Lucia (43)     X      8.8 
 
Table 2.3 Prevalence of COAG in different racial groups estimated from major epidemiological 
studies. The studies have been arranged in order of increasing prevalence to show the range of 
values found. The symbol X shows the majority race within each study. The racial groups shown 
were those adopted in the present study. 
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2.3.3 Sex 
Opinions differ as to whether sex is a risk factor in COAG (45, 131, 132).  Some studies have shown 
that males are more at risk (42, 44, 133), while others indicate that females have a greater risk 
(134).  Sex was therefore included in this study to see if a link could be established.  
2.3.4 Family history 
Some studies have reported lifetime risk of developing COAG  in first degree relatives is 
approximately 10x greater than those without a family history of the condition (135).  Having siblings  
with the disease raises the risk more than having a parental family history (136).  More risk is also 
associated with a maternal rather than a paternal family history  (137).  Given these findings, the 
present study included any recorded family history involving the mother, father and/or one or more 
siblings. 
2.3.5 Reason for referral 
Reason(s) for referral (RFR) recorded in the present study were raised IOP, suspect optic discs and 
suspect visual fields.  The purpose of this was to follow up the recommendation of a previous study 
to minimise false positives by combining test data relating to IOP, optic disc and visual field 
assessment (138).  It has been suggested that basing referrals on combined test results may 
provide a more cost effective means of reducing false positives than using accredited community 
optometrists (105). 
2.3.6 Intra Ocular Pressure  
Raised IOP is an important risk factor for COAG (139) and its reduction and control is the goal of 
treatment (99).  Reducing the IOP by 20% lowers the risk of progression to COAG  within 5 year 
period by 60% (140).  Each 1mmHg rise in IOP is associated with a 10% increased risk of COAG 
progression (141). 
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The author and his two colleagues measured IOP using a Haag Streit AT900 Model T GAT and 
non-disposable prisms with a slit lamp biomicroscope. 
The IOP values were grouped (<21mmHg, 21-25mmHg, 25-32mmHg, >32mmHg) according to the 
NICE guidelines (see table 1.4 in section 1.6.8). 
The inter-ocular difference in IOP (IOP diff) in both eyes was grouped as <3mmHg, 3-6mmHg, 
>6mmHg as the risk of POAG increases by 6% and 57% for IOP diffs of 3mmHg and greater than 
6mmHg, respectively (142).   
Even in NTG, it has been found that an IOP difference, in 86% of cases, causes greater damage in 
the eye with the highest pressure (143). 
2.3.7 Optic Nerve Head Assessment 
Optic nerve head assessment involved the use of dilated stereoscopic slit lamp biomicroscopy (JG 
and NOK – Haag Streit BQ900, DH – Topcon PS30) with a Volk lens (JG and DH – 66D, NOK – 
Digital 1x) (see section 1.8.3).  
The vertical disc size (VDS) was recorded because larger optic discs tend to have larger cup to disc 
ratios (144).  The measurement of VDS is particularly important when assessing both the amount of 
cupping and neuroretinal rim tissue in a disc for possible COAG (144-146).  Those of African 
descent have been shown to have larger optic discs than whites (147, 148) which, combined with 
the higher prevalence of the disease in Africans, has led to the notion that larger optic discs are a 
risk factor for COAG (149).  However, there is no evidence that the size of an optic disc is an 
independent risk factor for COAG (150). 
As patients seen by the author and his two colleagues were more often Caucasian, VDS was 
grouped (<1.4mm, 1.4-1.7mm, >1.7mm) according to a previous study carried out on a 
predominantly Caucasian population (151). 
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The vertical cup-to-disc ratio (VCDR) was expressed as a percentage.  The superior and inferior 
poles of the neural retinal rim are preferentially damaged in COAG (152).  COAG causes the cup-to-
disc ratio to increase most in the vertical meridian (153).  In keeping with this, the VCDR is a slightly 
better predictor for the development of COAG than the horizontal cup disc ratio (140).   
Every 0.1mm increase in vertical cupping increases the risk of COAG by 1.3 times (140).  The 
VCDR also increases at a faster rate in early stages of COAG compared to the horizontal cup-to-
disc ratio (154). 
Approximately 98% of healthy eyes have a VCDR of less than 65% (155).  Cut-off values that 
enable VCDR to distinguish healthy eyes from those with COAG have ranged from 50% (144) to 
70% (156).  The VCDR groups (50%, 50-70%, >70%) adopted in the present study broadly 
encompassed these suggested cut-off values.  
COAG is a bilateral condition which is frequently asymmetric (157).  Inter-ocular differences in 
VCDR (VCDR diff) can occur with COAG (158, 159).  The VCDR diff was expressed as a 
percentage in the present study.  It was grouped (<20%, 20-30%, >30%) to reflect previous findings 
that VCDR diffs of 20% and 30% were found three and ten times more often, respectively, in COAG 
compared to healthy eyes (158). 
2.3.8 Central Corneal Thickness 
Central corneal thickness (CCT) may influence the accuracy of GAT in the diagnosis and 
management of COAG (160).  Thin and thick corneas can result in artificially low and high IOP 
readings, respectively (161).  CCT is also an important risk factor for the development of COAG 
(140) with an increased risk of 1.4 for every 40 microns reduction in CCT (162).  Measurement of 
CCT is used in conjunction with GAT and age to decide whether treatment for COAG or OHT should 
begin (52) (see Table 1.4 in section 1.6.8).   
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The author and his two colleagues measured CCT (see section 1.8.3) using handheld ultrasound 
pachymetry (JG - Accutome Pachpen, DH – Pachmate, NOK – Pachmate 2).  The CCT 
measurements were grouped (<555 microns, 555-590 microns,>590 microns), in the present study, 
according to the NICE guidelines (see Table 1.4 in section 1.6.8). 
2.3.9 Visual Fields 
Visual field (VF) assessment is important in the diagnosis and management of COAG (see section 
1.5.3.1).  NICE recommended the SITA 24-2 testing strategy as the reference standard for 
measuring the VF (see section 1.6.4).  The author and his two colleagues measured the VF using 
the Zeiss Humphrey Visual Field Analyser (VFA: JG- model 720i, DH – model 720, NOK – model 
720i) with the SITA FAST 24-2 testing strategy.  This testing strategy was the method preferred by 
the Lead Consultant Ophthalmologist overseeing the COT (Prof Ejaz Ansari, see section 1.8.2) and 
was also used in the HES glaucoma clinic in the area covered by the COT.  Grouping of VF defects 
(mild, medium, severe) followed the Hodapp-Anderson-Parrish (HAP) grading system (163).  The 
original HAP grading system was applied to the SITA standard 30-2 testing strategy, but other 
studies have applied it to the SITA fast 30-2 testing strategy (164).  A description of the application 
of the HAP grading system to the SITA fast 24-2 testing strategy now follows.   
A mild defect was recorded if (i) the mean deviation was no worse than -6db and, on the pattern 
deviation plot, (ii) less than 25% of points were depressed below the 5% level, (iii)less than 15% of 
points were depressed below the 1% level and (iv) no point within the central 5 degrees had a  
sensitivity of less than 15db (163). 
A moderate defect was recorded if (i) the mean deviation fell between -6db and -12db and, on the 
pattern deviation plot,  (ii) less than 50% of the points were depressed below the 5% level, (iii) less 
than 25% of the points were depressed below the 1% level, (iv) no point within the central 5 degrees 
had a sensitivity of less than 0db and (v) only one hemi field contained a point with a sensitivity of 
less than 15db within 5 degrees of fixation (163). 
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A severe defect was recorded if (i) the mean deviation was worse than -12db and, on the pattern 
deviation plot, (ii) more than 50% of the points were depressed below the 5% level,  
(iii) more  than 25% of points were depressed below the 1% level, (iv) any point within the central 5 
degrees had a sensitivity of less than 0db and (v) both hemi fields contained points with a sensitivity 
of less than 15db within 5 degrees of fixation (163). 
2.3.10 Management 
Management decisions were grouped (Dis, Fup, Refer) as described in section 1.8.3. 
2.4 Summary 
This chapter has provided a detailed description of the methods used by the three COT members 
who participated in this study and the grouping of clinical data to allow the use of likelihood ratios 
with multiple cut-off points.  A preliminary analysis of the data is described in the next chapter.  
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Chapter 3: Preliminary analyses 
3.1 Introduction 
A preliminary analysis of the data collected, as described in chapter 2, is provided in this chapter. 
The broad objectives of the chapter are to: 
1. Show the distribution of the COT’s clinical test findings according to the multiple cut-off 
points described in chapter 2;
2. Determine whether the clinical test findings were equally distributed across the three COT 
members (JG, DH and NOK);
3. Present a series of analyses describing the association between each clinical test and COT 
management outcomes (Dis, Fup or Refer);
4. To examine the influence of CCT on GAT-IOP and to show how it might impact on the 
agreement between the referrals made to the COT for raised IOP and COT measurements 
of IOP;
5. To examine the influence of VDS on VCDR;
6. To compare RFRs for suspect VF and COT measurements of HPA;
7. To examine First Discharge Rates (FDRs) and cost savings of the COT;
8. To rank COT tests in order of the strength of their statistical associations with COT 
management outcomes. 
3.2 Statistical methods 
Frequencies were compared using Chi-square for R x C contingency tables (165).  This form of Chi-
square test was also used to carry out analyses exploring the strength of associations between 
each clinical test and the COT management outcomes (Dis, Fup or Refer – chapter 2 section 
2.3.10).  
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Tables of contributions, the degrees of freedom associated with these Chi-square tests varied from 
1 to 10.  Power analyses, conducted using GPower3.1 (166), indicated that Chi-square tests could 
detect medium size effects at the conventional alpha and beta levels of, respectively, 0.05 (equating 
to the 95% level of statistical significance) and 0.2 (equating to 80% power), for total sample sizes 
of between 88 and 181 people for, respectively, 1 to 10 degrees of freedom.  All Chi-square tests 
presented in this chapter exceeded these minimum sample size requirements.  Pearson’s 
correlation coefficient (r), the coefficient of determination (r2), analysis of variance (ANOVA) and 
linear regression by the method of least mean squares (167) was carried out to determine 
relationships between CCT versus GAT-IOP and VDS versus VCDR.  Power calculations (also 
using GPower3.1) revealed that linear regression could detect medium size effects at the alpha and 
beta levels mentioned above for a sample sizes of 82.  The minimum sample requirement was far 
exceeded in the analyses presented.      
3.3 Distribution of the COT clinical test findings 
The first objective was to show the distribution of the COT clinical test findings according to the 
multiple cut-off points described in chapter 2.  Figures 3.1 to 3.13 show the distribution of clinical 
test findings across the samples seen by each COT optometrist (JG, DH, NOK) contributing data to 
the study.  Table 3.1 summarises the findings in Figures 3.1 to 3.13 by showing the percentage of 
cases falling in each of the multiple COT test categories after pooling the data from the 3 COT 
optometrists.  
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Figure 3.1. Distribution of age across the sample seen by each COT optometrist (JG, DH, NOK) 
contributing data to this study N =1006. 
Figure 3.2 Distribution of race across the sample seen by each COT optometrist (JG, DH, NOK) 
contributing data to this study N=1006. 
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Figure 3.3 Distribution of sex across the sample seen by each COT optometrist (JG, DH, NOK) 
contributing data to this study N=1006. 
 
 
Figure 3.4 Distribution of Family history across the sample seen by each COT optometrist (JG, DH, 
NOK) contributing data to this study N=315. 
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Figure 3.5 Distribution of RFR across the sample seen by each COT optometrist (JG, DH, NOK) 
contributing data to this study N=1006. 
                                                                                                                                                                                                     
 
Figure 3.6 Distribution of GAT IOP across the sample seen by each COT optometrist (JG, DH, 
NOK) contributing data to this study N=1006. 
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Figure 3.7 Distribution of IOP diff across the sample seen by each COT optometrist (JG, DH, NOK) 
contributing data to this study N=1006. 
 
 
Figure 3.8 Distribution of VDS across the sample seen by each COT optometrist (JG, DH, NOK) 
contributing data to this study N=1006.  
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Figure 3.9 Distribution of VCDR across the sample seen by each COT optometrist (JG, DH, NOK) 
contributing data to this study N=1006. 
 
 
Figure 3.10 Distribution of VCDR diff across the sample seen by each COT optometrist (JG, DH, 
NOK) contributing data to this study N=1006.  
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Figure 3.11 Distribution of CCT across the sample seen by each COT optometrist (JG, DH, NOK) 
contributing data to this study N=1006. 
 
  
Figure 3.12 Distribution of HPA classification of VFA test across the sample seen by each COT 
optometrist (JG, DH, NOK) contributing data to this study N=1006.  
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Figure 3.13 Distribution of COT management decisions across the sample seen by each COT 
optometrist (JG, DH, NOK) contributing data to this study N=1006
. 
Clinical Test Percentage of cases falling in each category 
Age (years) <40 (6%), 40-49 (13.4%), 50-59 (24.1%), 60-69 (27.1%), 70-79 (21.7%), 
80+ (7.8%)  
Race  Caucasian (95.9%), Asian (1.7%), Afro-Caribbean (1.2%), African (0.3%), 
Hispanic (0.9%)   
Sex Female (52.1%), Male (47.9%)  
FHG Mother (14.2%), Father (10.9%), Sibling (6.2%) 
RFR IOP (40.6%), Discs (34.9%), VF (13.6%), IOP/Discs (4.8%), IOP/VF 
(0.9%), VF/Discs (5.3%)  
GAT IOP (mmHg) <21 (76.8%), 21-25 (18.0%), >25-32 (4.3%), >32 (0.9%)  
IOP diff (mmHg)  <3 (92.0%), 3-6 (5.3%), >6 (2.7%)  
VDS (mm) <1.4 (8.6%), 1.4-1.7 (43.6%), 1.8+ (47.7%)  
VCDR  <50 (49.3%), 50-70 (44.6%), >70 (6.1%)  
 VCDR diff  <20 (86.0%), 20-30 (12.0%), >30 (2.0%)  
CCT (nm) <555 (44.0%), 555-590 (37.2%), >590 (18.8%)  
VFA HPA Mild (9.0%), Moderate (4.4%), Severe (2.9%)  
Management Dis (79.3%), Fup (7.0%), Refer (13.7%)  
 
Table 3.1 Percentage of cases falling in each of the multiple categories for each COT test pooled 
across the 3 COT optometrists (JG, DH, NOK) contributing data to this study. 
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3.4 Were clinical and biographical test findings equally distributed across the 3 COT optometrists? 
The second objective was to determine whether the clinical and biographical test findings shown in 
Figures 3.1 to 3.13 were equally distributed across the three COT optometrists (JG, DH and NOK).  
Analysis was carried out to explore any inhomogeneity between the samples seen by each COT 
optometrist as this could affect the outcomes of investigations into the consistency of naïve Bayes 
applied separately to their data (see chapter 4).  Table 3.2 summarises the findings and shows that 
6 out of the 13 clinical tests showed inhomogeneous distributions between the COT optometrists. 
Clinical test Chi-square, degrees of freedom (df), P-value 
Age  12.65, df = 10, P = NS    
Race  27.05, df = 8, P <0.001    
Sex 0.37, df = 2, P = NS   
FHG 13.74, df = 4, P <0.01  
RFR 13.51, df = 10, P = NS   
GAT IOP 7.41, df = 6, P = NS   
IOP diff  2.58, df = 4, P = NS  
VDS  290.40, df = 4, P <0.0001 
VCDR  9.03, df = 4, P = NS  
VCDR diff  40.83, df = 4, P <0.0001 
CCT  10.67, df = 4, P <0.05  
HPA class 12.26, df = 4, P <0.05  
Management 6.37, df = 4, P = NS  
 
Table 3.2 Summary of Chi-square tests carried out to determine the homogeneity of the samples 
seen by the 3 COT optometrists (JG, DH, NOK) contributing data to this study. Instances of 
statistically significant inhomogeneity are shown in bold. 
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3.5 Associations between clinical tests and COT management decisions 
The third objective was to present a series of analyses describing the associations between each 
clinical test and the COT management outcomes.  Figures 3.14 to 3.25 show the percentage 
discharge (Dis), follow-up (Fup) and (Refer) for each of the multiple COT test categories after 
pooling the data from the 3 COT optometrists.  Table 3.3 summarises the findings of these statistical 
tests. 
 
 
Figure 3.14 Percentage Dis, Fup and Refer for each age group, pooled across the three COT 
optometrists (JG, DH, NOK) contributing data to this study N=1006. 
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Figure 3.15 Percentage Dis, Fup and Refer for each racial group, pooled across the three COT 
optometrists (JG, DH, NOK) contributing data to this study N=1006. 
 
 
Figure 3.16 Percentage Dis, Fup and Refer for males and females, pooled across the three COT 
optometrists (JG, DH, NOK) contributing data to this study N=1006. 
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Figure 3.17 Percentage Dis, Fup and Refer for each family history category, pooled across the three 
COT optometrists (JG, DH, NOK) contributing data to this study N=1006. 
 
 
Figure 3.18 Percentage Dis, Fup and Refer for each RFR category, pooled across the three COT 
optometrists (JG, DH, NOK) contributing data to this study N=1006. 
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Figure 3.19 Percentage Dis, Fup and Refer for each GAT IOP category, pooled across the three 
COT optometrists (JG, DH, NOK) contributing data to this study N=1006. 
 
 
Figure 3.20 Percentage Dis, Fup and Refer for each IOP diff category, pooled across the three COT 
optometrists (JG, DH, NOK) contributing data to this study N=1006. 
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Figure 3.21 Percentage Dis, Fup and Refer for each VDS category, pooled across the three COT 
optometrists (JG, DH, NOK) contributing data to this study N=1006. 
 
 
Figure 3.22 Percentage Dis, Fup and Refer for each VCDR category, pooled across the three COT 
optometrists (JG, DH, NOK) contributing data to this study N=1006. 
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Figure 3.23 Percentage Dis, Fup and Refer for each VCDR diff category, pooled across the three 
COT optometrists (JG, DH, NOK) contributing data to this study N=1006. 
 
 
Figure 3.24. Percentage Dis, Fup and Refer for each CCT category, pooled across the three COT 
optometrists (JG, DH, NOK) contributing data to this study N=1006. 
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Figure 3.25 Percentage Dis, Fup and Refer for each HPA classification, pooled across the three 
COT optometrists (JG, DH, NOK) contributing data to this study N=1006. 
 
Clinical  
tests 
Influence on referral rates 
(Chi-square, degrees of freedom (df), P-value) 
Agrees with 
other studies 
Disagrees 
other studies 
Age Referral rates increased with age 
(Chi-square = 77.34, df = 10, P = <0.0001) 
(168) 
 
Race Hispanics and Africans were referred most often   
(Chi-square = 28.55, df = 8, P = <0.001) 
(41, 47, 48, 
121, 130) 
 
Sex Males were referred most often 
(Chi-square = 12.06, df = 2, P = <0.01) 
(42, 44, 133) (134) 
Family 
history 
Family history of COAG did not influence referrals 
(Chi-square = 4.72, df = 4, P = NS). 
(140) (135, 136) 
RFR Multiple RFRs were referred most often 
(Chi-square = 97.92, df = 2, P = <0.0001) 
(110, 169) 
 
GAT IOP Referral rates increased with GAT IOP  
(Chi-square = 282.48, df = 6, P = <0.0001) 
(79, 139, 140, 
170-172) 
 
IOP Diff Referral rates increased with IOP diff  
(Chi-square = 338.59, df = 4, P = <0.0001) 
(142) 
 
VDS Referral rates increased as VDS reduced  
(Chi-square = 29.25, df = 4, P = <0.0001) 
 
(150) 
VCDR Referral rates increased with VCDR 
(Chi-square = 311.24, df= 4, P = <0.0001) 
(140) 
 
VCDR 
Diff 
Referral rates increased with VCDR Diff  
(Chi-square = 279.88, df = 4, P = <0.0001) 
(158) 
 
CCT Referral rates increased as CCT decreased 
(Chi-square = 39.62, df = 4, P = <0.0001) 
(140, 162) 
 
HPA 
Class 
Referral rates increased with HPA severity 
(Chi-square = 849.79, df = 6, P = <0.0001) 
(163) 
 
 
Table 3.3 Associations between each clinical test and COT management outcomes showing 
agreement or disagreement with previous studies. 
No Defect Mild Mod Severe
Dis 95% 1% 0% 0%
Fup 4% 29% 18% 0%
Refer 1% 70% 82% 100%
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Table 3.3 shows that all but one of the findings of the present study agreed with at least one 
previous study.  The association between VDS and COT management decisions was the only 
finding that disagreed with previous research.  Figure 3.21 shows that referral rates increase as 
VDS is reduced.  These results disagree with a previous study (149) that found no evidence for 
optic disc size being an independent risk factor for COAG (150).  It must be remembered that only 
univariate analyses are shown in this chapter.  Analyses of this type are prone to showing 
erroneous associations caused by hidden covariations between variables.  There is, however, 
another possible explanation for the association found in the present study.  Table 3.2 shows that 
there was a highly statistically significant degree of inhomogeneity between the VDS distributions 
(see Figure 3.8) found in the samples seen by each COT optometrist.  This finding was surprising 
as all three used the same equipment for recording VDS (see section 2.3.7).  
Despite agreement with previous studies, the association between racial groups and COT 
management decisions must be interpreted cautiously as the study sample was predominantly 
Caucasian.    
The association between RFR and COT management decisions was revisited.  Figure 3.26 shows 
that referrals into the COT with multiple RFR had lower percentage discharge and higher 
percentage referral rates than those with a single RFR.  The association was statistically significant 
(Chi-square = 97.92, degrees of freedom = 2, P = <0.0001) and suggests that false positive 
referrals would reduce if optometrists referred patients with more than one suspicious test finding. 
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Figure 3.26 Percentage Dis, Fup and Refer for single and multiple RFRs, pooled across the three 
COT optometrists (JG, DH, NOK) contributing data to this study N=1006. 
 
3.6 The influence of CCT on GAT IOP  
The fourth objective was to examine the influence of CCT on GAT IOP in order to show how it might 
impact on the agreement between (a) the referrals made to the COT for raised IOP and (b) COT 
measurements of IOP.  Higher IOP readings are associated with increased CCT (173-175).  Figure 
3.27 shows the statistically significant linear relationship between GAT IOP and CCT found in the 
present study (r = 0.027, p <0.001).  For every 50 microns increase in CCT there was a 0.96 mmHg 
increase in IOP.  The rate of increase found is in keeping with previous studies which reported 
between 0.90 to 1.00 mmHg increase IOP for every 50 microns of CCT increase (174). 
 
 
 
 
Single Finding Multiple Finding
Dis 84% 47%
Fup 6% 9%
Refer 10% 44%
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
74 
 
 
 
Figure 3.27 Relationship between GAT IOP and CCT measured in the present study N=1006. 
 
The question was, could variations in CCT account for the occurrence of cases referred into the 
COT with raised IOP that were subsequently found to have normal IOP?  Figure 3.28 shows that 
405 cases were referred in to the COT with raised IOP.  Of these, only 159 (39%) had raised GAT 
IOPs (>21mmHg). 
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Figure 3.28 Frequencies of cases that had been referred in to the COT with raised IOP but were 
subsequently found to have normal (norm) or raised GAT IOPs (>21mmHg) after dividing the 
sample into those with thin, medium (med) or thick CCTs  N=405. 
 
Several reasons may account for this finding.  Firstly, Non-Contact Tonometry (NCT) tends to read 
higher than GAT (176, 177).  Differences of at least 2 mmHg have been reported when comparing 
various tonometers to GAT (178).  NCT is also more affected by CCT than is GAT (179) and gives a 
greater overestimation of IOP with thicker CCT and steeper curvatures than occurs with GAT (180).  
The majority of community optometrists use NCT as the primary device for recording IOP (181, 
182).  Indeed, a study on the accuracy of referrals to a glaucoma clinic from community optometrists 
revealed that only 2% were based on contact tonometry (109).  All COT tests were carried out at a 
single COT visit, importantly this leads to limitation with respect to regression to the mean (RTM).  
RTM may bias an investigation when it is based upon an initial value without a control group (183).  
For example in this study IOP was measured at one given time.  GAT IOP is known to have diurnal 
variations (184). 
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An attempt was made to determine whether variations in CCT could explain the observed 
differences between (a) the referrals made to the COT for raised IOP and (b) COT measurements of 
IOP.  Chi-square was used to compare frequencies of cases that had been referred in to the COT 
with raised IOP but were subsequently found to have normal (norm) or raised GAT IOPs 
(>21mmHg) after dividing the sample into those with thin, medium (med) or thick CCTs.  The 
expectation was that, if CCT variations were influential, a greater proportion of cases with thicker 
corneas would be found to have normal GAT IOP.  Figure 3.28 shows some evidence for this as the 
proportion of cases with normal GAT IOP increased from (64 / [64 + 47] =) 0.577 in those with thin 
CCTs, through (95 / [95 + 65] =) 0.594 in those with medium CCTs to (87 / [87 + 47] =) 0.649 in 
those with thick CCTs.  However, the trend was not statistically significant (Chi-square = 1.55, 
degrees of freedom = 2, P = NS).  
3.7 The influence of VDS on VCDR 
The fifth objective was to examine the influence of VDS on VCDR. Previous research has found that 
VCDR increases with VDS (144, 151, 185).  Figure 3.29 shows the statistically significant linear 
relationship between VCDR and VDS found in the present study (r = 0.335, p <0.0001).  For every 1 
mm increase in VDS there was a 24% increase in the VCDR.  The rate of increase found was 
similar to that reported in a previous study (27%) (186). 
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Figure 3.29 Relationship between VCDR and VDS N=1006. 
 
3.8 Comparison between RFRs for suspect VF and COT measurements of HPA 
The sixth objective was to compare reasons for referrals in to the COT (RFRs) for suspect VF and 
subsequent COT measurements of HPA.  Some interesting observations arose.  On the one hand, 
16% of the cases referred in to the COT with suspect VF subsequently had normal VFs according to 
the HPA classification system.  On the other hand, some (9%) of cases had HPA defects having not 
been referred in to the COT with suspect VF.  
One reason for these discrepancies could be learning affects (187).  The COT effectively repeats 
the VF test for at least a second time.  Previous literature has recommended repeat VF testing for 
borderline cases (187).  Simply repeating a VF test can improve patient understanding leading to 
greater reliability (188). 
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Another reason for the observed differences was likely to be that a variety of VF tests were used by 
optometrists who made referrals in to the COT (the VF test used was not recorded as part of this 
study).  Variations in VF test design are known to influence their ability to detect defects (189).  It 
might also be that no VF test had not been performed.  
 
3.9 FDRs and cost savings of the COT  
The seventh objective was to examine FDRs and cost saving bought about by the activities of the 
COT.  As explained in chapter 1 (section 1.8.1), the COT was established to allow a multi-
disciplinary approach to benefit patient care.  Due to increasing population demands and longevity, 
cost benefits are also important to the NHS and CCGs. 
A key finding of the present study relates to its high FDRs; where the patient is discharged following 
a COT appointment as no disease is present.  The FDR in the present study (79%, see Figure 3.13 
and Table 3.1) compares favourably with FDRs reported for other schemes (see Table 1.5) 
operated by specialist optometrists (38, 105, 113, 114) and non-specialist optometrists (111).  
Discharge rates may well have been higher than many schemes which use repeat measures or 
enhanced case finding as the COT truly does refine the referrals in accordance with NICE 
recommendation(115) with more extensive testing involving gonioscopy.  The extra evidence 
gathered by the COT would lead to some patients with the lower risk of conversion to COAG not 
being retained within the COT system compared to other schemes.  Interestingly, schemes which 
simply repeat measurements have a similar FDRs (105, 112).  So, although the COT can save 
considerable costs, it might be that the same or even greater savings can be made from simpler 
GRR schemes.  RTM may explain the tendency for high FDRs in simpler schemes. 
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The COT practitioner receives £65.65 per patient from the CCG for the first GRR visit.  The cost of 
equipment and other sundries such as ocular drugs are borne by the COT practitioner.  In 
comparison, the CCG currently pays the HES a consultant-led first attendance multi professional 
HES tariff of £125 x 1.1095 MFF; where MFF is the Market Forces Factor and amounts to £138.69 
(190).  The MFF is an estimate of unavoidable cost differences between healthcare providers 
dependent upon where they are located.  The £65.65 received by COT practitioners includes the 
MFF.  These figures allow a direct comparison of the costs of referral to the COT versus the HES 
(rounded down to the nearest pound).  The cost for the first visit of 1006 cases seen in the COT was 
(1006 x 65.65 =) £66,043 added to this were the costs of COT referrals to the HES of 138 cases for 
confirmation of POAG.  At £138.69 per case, which amounted to (138 x 138.69 =) £19,139.  So the 
total cost amounted to (66043 + 19139 =) £85,182.  In comparison, the cost of 1006 cases seen by 
the HES would have been (1006 x 138.69 =) £139,522.  The total cost saving was, therefore, 
(139,522 – 85,182 =) £54,340 which was (54,340 ÷ 1006 =) £54 per case.   Administration is fairly 
cost neutral as the same PCBS staff who are employed by the CCG are responsible for bookings on 
behalf of both the COT and HES. 
Previous studies (38, 105, 113) have reported cost savings varying from £9 (106) to £117 (113) per 
case.  Previously reported cost analyses have accounted for the cost of follow up appointments 
(105) or have made assumptions about the number of patients being seen and the minimum 
percentage that will not need to have been referred to the HES (38).  A limitation of the present 
study was that neither of these factors were built into the cost analysis for the COT.  
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3.10 Ranking of COT tests 
The final objective was to rank COT tests in order of the strength of their statistical associations with 
COT management outcomes.  The simplest method of doing this (Method A) was to rank tests in 
order of the Chi-square values shown in Table 3.3. However, the degrees of freedom (df) of a Chi-
square test is also important when establishing whether an association is statistically significant.  
Therefore, after seeking statistical advice (191), a second method of ranking tests (method B) was 
used in which Chi-square was divided by the degrees of freedom; Chi-square per degree of 
freedom.  The rationale behind the second method follows.  With 1 degree of freedom, a Chi-square 
value of >3.841 indicates a statistically significant association at the 95% level.  With 10 degrees of 
freedom, a Chi-square value of >18.31 indicates the same.  So, considering Chi-square alone 
(method A) could lead to overestimated strength of an association and corrupt test rankings.  
Dividing 18.31 by 10 gives a Chi-square per degree of freedom of 1.831 which is closer to 3.841.  
Though method B is not perfect, greater confidence in the outcomes can, at least, be inferred if its 
rankings match those of method A. 
Table 3.4 shows all COT tests ranked according to methods A and B.  Both methods gave a fairly 
consistent indication of the ranking positions of each test; with differences of no more than one 
ranked position.  The test ranks shown in Table 3.4 are compared to those based on likelihood 
ratios in chapter 4 (see Table 4.7). 
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Method A 
Test (Chi-square) 
Method B 
Test (Chi-square per degree of freedom) 
HPA class (850) HPA class (142) 
IOP diff (339) IOP diff (85) 
VCDR (311) VCDR (78) 
GAT IOP (282) VCDR diff (70) 
VCDR diff (280) GAT IOP (47) 
RFR (98) RFR (15) 
Age (77) CCT (10) 
CCT (40) Age (8) 
VDS (29) VDS (7) 
Race (29) Sex (6) 
Sex (12) Race (4) 
Family History (5) Family History (1) 
 
Table 3.4 COT tests ranked in order of the strength of their statistical associations with COT 
management outcomes. Rankings are compared for two methods: Method A based on Chi-square 
and method B based on Chi-square per degree of freedom. Differences in ranking between the two 
methods are highlighted in bold. 
 
3.11 Summary  
Key findings arising from the 8 objectives outlined in section 3.1 of this chapter are listed below: 
• Figures 3.1 to 3.13 and Table 3.1 show the distribution of the COT’s clinical test findings, 
according to the multiple cut-off points introduced in chapter 2, for each of the optometrists 
that contributed data to this study. 
• Findings summarised in Table 3.2 indicated that 6 out of the 13 COT clinical tests showed 
inhomogeneous distributions between the COT optometrists.  The inhomogeneity between 
observers, particularly with VDS is an important limitation of the study.  This could also affect 
the outcomes of investigations into the consistency of naïve Bayes applied separately to 
their data in chapter 4. 
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• Figures 3.14 to 3.25 and Table 3.3 show the relationship between each clinical test and the 
COT management outcomes.  All but one of the findings (that relating to VDS) corroborated 
previous research.  Study of the influence of race was limited as the sample was 
predominantly Caucasian.  The ethnicity of the sample does not allow for judgements to be 
made on any other ethnic group than Caucasian. 
• Referrals to the COT were more likely to indicate COAG if based on multiple RFRs. 
• GAT IOP increased with CCT (Figure 3.27), as had been reported in previous studies.  
However, variations in CCT did not explain observed differences in referrals made to the 
COT for raised IOP and COT measurements of IOP (Figure 3.28). 
• VCDR increased with VDS (Figure 3.29), as had been reported in the previous literature. 
• Observed differences between referrals made to the COT for suspect VF and COT 
measurements of HPA were considered to arise from the use of a variety of different VF 
tests by community optometrists. 
• FDRs compared favourably to those reported for other GRR schemes.  Estimated cost 
savings of £54 per case arose from the activities of the COT. 
• COT tests were ranked in order of the strength of their statistical associations with COT 
management outcomes (Table 3.4) for later comparison with ranks based on likelihood ratios 
in chapter 4 (see Table 4.7). 
Naïve Bayes is applied in the next chapter in order to determine whether it can provide useful 
diagnostic support in the referral refinement of COAG. 
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Chapter 4: Can naïve Bayesian artificial intelligence predict COT decisions? 
4.1 Introduction  
As described in chapter 1, the primary aim of this study was to determine whether naïve Bayesian 
artificial intelligence (Bayes) could be used to predict the decisions of COT optometrists (JG, DH 
and NOK).  This chapter provides an account of how the primary aim was achieved.  Bayes was 
applied as described in section 1.4.  The clinical data that Bayes was applied to is that summarised 
in Table 3.1 (section 3.3).  The material presented in this chapter represents completion of the 
following objectives: 
• To establish the best means of determining the accuracy of Bayes from current literature on 
machine learning (section 4.2);  
• To determine the extent to which COT clinical test findings were truly independent of each 
other; the key assumption of naïve Bayes (section 4.3); 
• To plot learning curves in order to determine how much data is required to achieve 
maximum learning when using Bayes (section 4.4);  
• To investigate the transferability of likelihood ratios generated during the application of 
Bayes (sections 4.5 and 4.7);  
• To determine the accuracy of Bayes and, in the event that accuracy was insufficient, to 
explore any improvement of accuracy using cost-sensitive learning (section 4.6); 
• To determine, using likelihood ratios, whether redundancy existed in the COT clinical data 
(section 4.8);  
• To rank COT clinical tests (for comparison with those shown in section 3.10) based upon 
their likelihood ratios (section 4.9). 
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4.2 Evaluating accuracy 
There are numerous methods of evaluating the accuracy of learning schemes.  These are all based 
on confusion matrices that show the frequency of correct and incorrect decisions made by the 
learning scheme (see Table 4.4 later).   
Baseline performance of any learning scheme is based on ZeroR; the prior probability of the 
commonest clinical decision.  Evaluation of the learning scheme itself involves learning from a 
training dataset and testing what has been learned on a testing dataset.  Using the same dataset for 
training and testing leads to optimistic predictions of accuracy but is considered to provide an 
estimate of the best possible performance of a learning scheme (192).  Ideally, the testing dataset 
should not be involved in training but an acceptable alternative is to perform randomised stratified 
tenfold cross-validation.  Here, the dataset is divided into 10 folds.  The cases included in each fold 
are selected randomly and stratification ensures that each clinical decision (Dis, Fup and Refer) is 
equally represented in each fold.  Each fold in turn is then assigned as the testing dataset with all 
other folds used for training.  Treating the data in this way is considered to offer the most realistic 
prediction of the accuracy of the learn scheme (192).  
Measures of accuracy are also numerous (193).  The simplest of these is Rand accuracy and is the 
probability that the learning scheme makes a correct decision (193).  Cohen’s Kappa is ubiquitous 
and provides an estimate of the agreement between the learning scheme and the COT optometrists 
after removing the proportion of agreement considered to be due to chance.   
Accuracy of a learning scheme can also be expressed in the form of sensitivity (AKA recall, true 
positive rate and hit rate) and specificity (AKA inverse recall and true negative rate), both terms 
being well known to clinicians (193).  These can be combined into a single term called informedness 
which is an estimate of the ability of a learning scheme to correctly test positive or negative above 
chance (193).   
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Informedness cannot, however, be used to estimate how well the learning scheme predicts an 
outcome.  To do this, a term called markedness combines predictive values for positive (PPV, AKA 
precision) and negative (NPV, AKA inverse precision) findings and indicates how well the learning 
scheme makes these predictions above chance (193).  Other frequently used estimates of learning 
scheme performance are the area under the receiver operating curves (AUC) and the Matthew’s 
correlation coefficient (MCC).  The F-measure, which combines sensitivity and PPV, has been 
considered biased to predictions of positive outcomes; while the machine learning community 
seems to be solely interested in detection of positive outcomes, the healthcare community is just as 
interested in negative outcomes (193).   
Learning curves (see section 1.4.3) provide a means of determining how much data is required 
before the learning scheme achieves maximum accuracy (193).  
Incorrect decisions made by learning schemes carry costs. These can be overcome by adopting 
cost sensitive learning (190).  Cost learning takes misclassification of costs into account ,treating 
each of these misclassifications in a different manner in an effort to reduce the total cost (194).  A 
person discharged when they should have been followed up or referred is at risk of avoidable 
blindness.  On the other hand, a person referred when they should have been followed up or 
discharged suffers avoidable distress and the receiving HES glaucoma unit suffers avoidable 
burden.  These costs are difficult to estimate exactly but adding differential costs to the learning 
scheme may reduce the costs of incorrect decisions (192).          
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4.3 Correlations between clinical tests 
Table 4.1 shows that many of the clinical tests were inter-correlated.  The data, therefore, did not 
obey the primary assumption of naïve Bayes’; that all clinical tests are independent of each other.  
Despite tests not being independent high levels of accuracy were anticipated as described (section 
1.4). 
Kendall’s rank correlation was used for all tests as the data variables were discrete (bucketed) in 
nature.  Spearman’s correction was not used as this would be affected by how far the ranks were 
apart.  A Bonferoni correction was considered which adjusts probability due to the risk of increased 
type 1 errors when making multiple statistical tests (195).  The use of this correction has been 
considered to be contentious (195) as If applied to this data it was felt the number of false negatives 
would increase and reduce power.  Furthermore this correction can often be regarded as being too 
conservative (195)  and that if it were applied to this data then it could look like it was less inter 
related than initially thought so was not used in this study.  Had this correction been used in this 
study the Bonferoni correction alpha adjusted level would be 0.05/77= p=0.00065. 
 
 
 
 
 
 
 
 
  
87 
 
 
 
ag
e 
FH
 
R
FR
 
IO
P 
IO
P 
di
ff 
VD
S 
VC
D
R
 
VC
D
R
 d
iff
 
C
C
T 
H
PA
 
M
an
ag
em
en
t 
race -0.11    0.09  0.10  -0.07 0.07 0.09 
sex -0.07 0.08   -0.07  -0.13   -0.12 -0.09 
age   0.10 0.09 0.15  0.17 0.10 -0.15 0.20 0.18 
FH    -0.04  0.11  -0.07  -0.10 -0.08 
RFR    0.12 0.12  0.26 0.16  0.28 0.27 
IOP     0.36 -0.14 0.09 0.16  0.32 0.39 
IOP diff      -0.07 0.17 0.33 -0.10 0.47 0.54 
VDS       0.16 -0.08  -0.12 -0.15 
VCDR        0.20 -0.19 0.31 0.35 
VCDR 
diff 
        -0.12 0.42 0.46 
CCT          -0.16 -0.16 
HPA           0.85 
 
Table 4.1 Matrix showing statistically significant (P < 0.05) inter-correlations (Kendall’s tau for 2-
tailed tests) between the clinical tests included in this study. Variables included race (Caucasian, 
Asian, Afro-Caribbean, African, Hispanic), sex (male, female), age (<40, 40-49, 50-59, 60-69, 70-79, 
80+), family history of COAG (FH, a count from 1 to 3 based on how many types of relative - 
mother, father and sibling – had glaucoma), reason for referral (RFR, a count from 1 to 3 based on 
how many suspicious signs - IOP, optic discs and/or VF – were present in the referral), GAT intra-
ocular pressure (IOP, mmHg: <21, 21-25, >25-32, >32), GAT inter-ocular difference in intraocular 
pressure (IOP diff, mmHg: <3, 3-6, >6), vertical disc size (VDS, mm: <1.4, 1.4-1.7, 1.8+), vertical 
cup disc ratio (VCDR, %: <50, 50-70, >70), inter-ocular difference in VCDR (VCDR diff, %: <20, 20-
30, >30), Central corneal thickness (CCT, <555, 555-590, >590) and visual field loss (HPA 
classification: mild, moderate, severe). 
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4.4 Learning curves 
As one of the COT optometrists (NOK) saw 69 cases, learning curves were constructed, using the 
AEL Bayes’ application (see section 1.4.3), for the first 69 case of all three COT optometrists.  
Learning was initially carried out on the first case followed by testing on all 67 cases. Learning was 
repeated a further 22 times, adding three more cases to the learning set each time prior to testing 
on all 69 cases.  Figure 4.1 shows that Bayes learned rapidly and achieved maximum Rand 
accuracy (between 94 and 99%) even before including all 69 cases in the learning process.  This 
suggested that lack of adherence to the naïve Bayes’ assumption of independence (see section 1.4) 
had little effect on accuracy.  
 
Figure 4.1 Learning curves constructed using the AEL Bayes’ application for the first 69 cases seen 
by each COT optometrist (JG, DH and NOK). 
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4.5 Initial investigation of transferability of LRs 
The three sets of likelihood ratios generated by the AEL Bayes’ application after learning from all 69 
cases seen by each COT optometrist should, in theory, have been transferable.  That is, the high 
Rand accuracy shown in Figure 4.1 should have been maintained when the likelihood ratios from 
one optometrist were tested on the clinical data of another, which was investigated and the results 
shown in Table 4.2.   
Training set Testing set Weighted average Rand accuracy Kappa 
JG JG 0.97 0.83 
 DH 0.81 0.37 
 NOK 0.90 0.60 
DH DH 0.97 0.87 
 JG 0.81 0.18 
 NOK 0.85 0.40 
NOK NOK 0.98 0.91 
 JG 0.94 0.63 
 DH 0.84 0.41 
 
Table 4.2. Investigation of the transferability of likelihood ratios generated from the 69 cases seen 
by each COT optometrist (the training set) and tested on their own clinical data and that of their 
colleagues (the testing set). 
 
The weighted average Rand accuracy was calculated from the three separate estimates of Rand 
accuracy for each COT management outcome (Dis, Fup, Refer).  Kappa is also shown in the table.  
It can be seen that Rand accuracy and kappa reduced when one optometrist’s likelihood ratios were 
applied to another’s clinical data.  These findings was disappointing as it indicated that likelihood 
ratios were not transferable.  The decision was made to re-calculate likelihood ratios on a dataset 
comprising 1006 cases pooled from all three COT optometrists. Maybe these would be more 
transferable. 
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4.6 Baseline, maximum and realistic predicted accuracy 
 
The purpose of this section was to determine baseline accuracy, maximum accuracy and the most 
realistic estimate of accuracy for 1006 cases, pooled from all three COT optometrists. 
The machine learning community suggest that ZeroR is the baseline accuracy against which the 
performance of a learning scheme, such as Bayes, should be judged (190).  ZeroR is equal to the 
prevalence of the most commonly occurring outcome.  In this case, it was discharge which occurred 
for 798 of the 1006 cases; a ZeroR of 0.79.  
Although training and testing on the same dataset is known to give over optimistic estimates of 
accuracy, the machine learning community suggest that this process does at least provide the 
maximum possible accuracy of a learning scheme (190). 
Randomised stratified tenfold cross-validation is an established method of estimating the most 
realistic accuracy of a learning scheme. 
Table 4.3 shows that surprisingly little difference arose between maximum and most realistic 
accuracy measured in terms of Rand accuracy, Kappa, informedness, markedness, AUC and MCC.  
The table also clearly shows that Fup was predicted relatively poorly compared to the other COT 
outcomes (Dis and Refer).  Rand accuracy appeared to be relatively unresponsive to variations in 
performance.  The other measures (informedness, markedness, AUC and MCC) varied a lot more 
and in different ways.  For example, Rand accuracy indicated that performance was about equal for 
the outcomes Dis and Refer.  However, informedness and AUC were highest for the outcome Refer 
while markedness and MCC was highest for the outcome Dis.  Variations in informedness reflected 
those in AUC; likewise, for variations in markedness and MCC.  Therefore, performance could be 
judged based on informedness and markedness alone.  
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ZeroR 
0.79 
Rand 
accuracy 
Kappa informedness markedness AUC MCC 
Maximum accuracy (trained and tested on same dataset) 
Overall 0.96 0.79 0.80 0.88 0.90 0.83 
Discharge 0.96 - 0.83 0.91 0.91 0.87 
FUP 0.94 - 0.31 0.68 0.65 0.46 
Refer 0.96 - 0.88 0.81 0.94 0.84 
Most realistic accuracy (randomised stratified tenfold cross-validation) 
Overall 0.95 
(0.02) 
0.76 
(0.05) 
0.78 
(0.07) 
0.85 
(0.06) 
0.89 
(0.03) 
0.82 
(0.06) 
Discharge 0.96 
(0.02) 
- 0.82 
(0.08) 
0.90 
(0.05) 
0.91 
(0.04) 
0.86 
(0.06) 
FUP 0.93 
(0.01) 
- 0.22 
(0.19) 
0.38 
(0.37) 
0.61 
(0.09) 
0.31 
(0.23) 
Refer 0.95 
(0.02) 
- 0.85 
(0.08) 
0.79 
(0.08) 
0.93 
(0.04) 
0.82 
(0.07) 
 
Table 4.3 Maximum and most realistic accuracy of naïve Bayes’ against the ZeroR baseline for 
1006 cases seen by the COT, pooled from the cases seen by JG, DH and NOK. Rand accuracy, 
informedness, markedness, area under the receiver operating curve (AUC) and Matthew’s 
correlation coefficient (MCC) are shown for all three COT outcomes (discharge, FUP and Refer) 
along with an overall weighted average. Kappa only applies to overall performance. Standard 
deviations arising from tenfold cross-validation are shown in brackets. 
 
This is interesting, given that Bayes’ theorem illustrates the ‘base rate fallacy’ (196) in which it is 
assumed that forward probability (measured in terms of sensitivity and specificity) is equal to 
backward probability (measured in terms of positive and negative predictive value).  In other words, 
‘base rate fallacy’ refers to misinterpretation of clinical data.   
In the context of, COAG, this refers to the mistaken belief that a positive result, for a COAG test with 
90% sensitivity and specificity, means that a patient has a 90% probability of having COAG.  At 
least one study has shown that 50% of medical practitioners make this mistaken interpretation 
(197).   
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In this context, informedness relates to forward probability (how probable is it that a learning 
scheme will predict an event given that the event is present) while markedness relates to backward 
probability (how probable is it that an event is present if a learning scheme has predicted that it is 
present).  Of the two, markedness is most important if the clinician wants to be certain that a 
prediction of referral is a good one and, in that sense, Bayes appears to work best for identifying 
individuals to be discharged.  Perhaps it is not surprising, given that far more cases were 
discharged than referred.  The poor performance for cases requiring Fup may also be explained by 
these being rarest of all of the COT outcomes.  Fups are the least common outcome which may be 
an artefact of the COT system because as described (section 1.7) the COT is a true GRR service 
with highly trained practitioners who can diagnose both OHT and suspect COAG, allowing patients 
of low risk of developing COAG to be discharged back to their community optometrists.  Equally 
local community optometrists know that they can re-refer patients back into the COT system if 
concerned at any subsequent examination.  
Arguably, a confusion matrix provides an even clearer indication of performance and one is shown 
in Table 4.4.  
 Actual 
Dis Fup Refer Totals 
Pr
ed
ic
te
d Dis 789 28 6 823 
Fup 2 22 6 30 
Refer 7 20 126 153 
Totals 798 70 138 1006 
 
Table 4.4 Confusion matrix for the predictions of naïve Bayes’ in which training and testing was 
carried out on all 1006 cases (giving rise to maximum accuracy) seen by the COT, pooled from the 
cases seen by JG, DH and NOK. Actual COT outcomes (discharge, Fup and Refer) are shown 
against those predicted.   
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Only one matrix is shown (corresponding to maximum accuracy in Table 3.3) because this 
represented the best possible performance of Bayes.  Table 4.4 shows that 27 (false referral rate = 
2.7%) cases were unnecessarily referred to the HES and 34 (false discharge rate = 3.4%) cases 
were discharged when they should have been followed up or referred.  Only 22 of the 70 Fups were 
correctly classified.  Randomised stratified tenfold cross-validation, a better indicator of the 
performance of naïve Bayes’, gave rise to slightly higher false referral and discharge rates (and 
standard deviations) of 3.1(1.5)% and 3.4 (1.6)%, respectively.  While false referrals would have led 
to avoidable burden on HES resources, false discharges are arguably more serious as these had 
the potential to lead to avoidable blindness. 
Could it be that making Bayes cost sensitive would remove the false discharges and referrals?  This 
was investigated by altering the weights of the naïve Bayes’ probability estimates for each COT 
outcome.  This was achieved by increasing the post-test probabilities by an ever increasing number 
until all the false discharges disappeared.  For example, one case that naïve Bayes’ incorrectly 
classed as requiring discharge but should have been classed as Refer had probability estimates of 
0.54 (Dis), 0.08 (Fup) and <0.01 (Refer).  Increasing the weight of the probability for Refer would 
have removed the error but will have increased false referrals to the HES and was, therefore, not 
considered to be an option.  More acceptable options were to reduce the weight of the probability 
for discharge or to increase the weight of that for Fup. 
Figure 4.2 shows that all 34 false discharges could be removed when the weight of the probability 
estimate for discharge was reduced by multiplying it by 0.005 (which appears as a value of 1 – 
0.005 = 0.995 on the horizontal axis of Figure 3.3).  However, this dramatically increased the 
number of false Fups (from 8 to 530) and refers (from 27 to 100) and resulted in a reduction in 
percentage Kappa (from 79 to 19%).  While this removed the risk of avoidable blindness, its costs in 
terms of a 60-fold increase in Fups and a 4-fold increase in referrals to the HES rendered the 
solution unworkable.   
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Figure 4.2 Effect of reducing the weight of the naïve Bayes’ probability estimate for discharge upon 
the number of false discharges, false Fups, false refers and percentage Kappa. Reduction of weight 
was brought about by multiplying the probability estimate by between 1 and 0.005. In order to depict 
progressively reducing weight from left to right, the value on the horizontal axis is equal to 1 minus 
the multiplier. The vertical axis has been truncated at 100 to make key elements of the graph 
clearer (obscuring the full increase in false Fups). 
 
Figure 4.3 shows that all 34 false discharges and 27 false refers could be removed when the weight 
of the probability estimate for Fup was increased by multiplying it by 180.  This, again, dramatically 
increased the false Fups (from 8 to 649) and reduced percentage Kappa (from 79 to 15%).  
Although this solution was safer than the previous one, the 80-fold increase in Fups rendered it just 
as unworkable. 
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Figure 4.3 Effect of increasing the weight of the naïve Bayes’ probability estimate for Fup upon the 
number of false discharges, false Fups, false refers and percentage Kappa. Increasing of weight 
was brought about by multiplying the probability estimate by between 1 and 180. The vertical axis 
has been truncated at 100 to make key elements of the graph clearer (obscuring the full increase in 
false Fups). 
 
At this point in the study it became apparent that Bayes could not be safely applied in a referral 
refinement centre.  The remaining sections of this study were, therefore, included for academic 
interest alone. 
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4.7 Further investigation of transferability of LRs 
 
Transferability was revisited by applying the LRs generated from the 1006 pooled cases to the 
subset of 69 cases of each COT optometrist (see section 4.4).  Here, the 10 estimates of each LR 
arising from randomised stratified tenfold cross-validation (in section 4.6) were averaged.  Table 4.5 
shows that LRs generated from the pooled data were more transferable as they resulted in higher 
weighted average Rand accuracy and Kappa values than were found in Table 4.2 when likelihood 
ratios generated from the 69 cases seen by each COT optometrist were tested on their colleagues’ 
cases.  However, unacceptably high false discharge (1.4 to 7.2%) and referral (1.4 to 4.3%) rates 
still remained.  Ultimately the lack of transferability between COT optometrists is most likely due to 
inhomogeneity between them. 
Training set Testing set Weighted average Rand 
accuracy 
Kappa 
pooled JG 0.98 (0.81 - 0.94) 0.82 (0.18 - 0.63) 
 DH 0.91 (0.81 - 0.84) 0.65 (0.37 - 0.41) 
 NOK 0.95 (0.85 - 0.90) 0.76 (0.40 - 0.60) 
 
Table 4.5. Re-investigation of the transferability of likelihood ratios generated from randomised 
stratified tenfold cross-validation on 1006 pooled cases (the training set) and tested on the 69 
cases, shown in Table 4.2, seen by each COT optometrist (the testing set). Resulting weighted 
average Rand accuracy and Kappa values are shown next to those that arose in Table 4.2 for ease 
of comparison.  
 
4.8 Redundancy 
 
Likelihood ratios were the means by which new evidence from each COT test raised or lowered the 
degree of belief that any one of the three COT outcomes (Dis, Fup or Refer) was most appropriate 
for a given case.   
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The size of each LR therefore indicated the relatively usefulness of each COT test.  Those tests with 
LRs close to 1 (indicating that they were of no clinical value) could possibly be removed as they 
were, arguably, redundant.  Redundancy was explored on the 1006 pooled COT cases by using 
positive LRs from randomised stratified tenfold cross-validation to rank clinical tests in descending 
order.  Naïve Bayes’ was repeated after removing clinical tests, one at a time, starting with those 
ranked lowest.  Kappa, false discharge rate and false referral rate were calculated for each run in 
order to determine how many clinical tests could be removed before performance reduced.  As 
three sets of positive LRs arose, relating to the three possible COT outcomes (Dis, Fup and Refer), 
the decision was made to rank clinical tests on the basis of LRs for the Refer outcome; as correct 
identification of cases requiring referral was considered most important.  Within this thesis we are 
concerned with the detection of COAG and redundancy explored which tests were most important 
and which could be excluded for this purpose, thus redundancy for the Dis and Fup outcomes were 
not ranked.  Systematically removing tests, those with lowest LR first, without a drop in accuracy 
means that those tests added nothing to diagnosis i.e. were redundant in our evidence for diagnosis 
of COAG. 
Figure 4.4 shows that percentage Kappa stayed within 76 to 82% until 33 of the 41 COT tests had 
been excluded, at which point it fell dramatically.  
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Figure 4.4 Effect of excluding COT tests one by one starting with those ranked lowest in terms of 
their positive LR for the outcome Refer. Naïve Bayes was repeated after each exclusion.  The 
number of false discharges, false referrals and percentage Kappa are shown after each exclusion. 
 
The number of false discharges, stayed at between 29 and 34 cases until 34 COT tests had been 
excluded, after which point it dramatically rose.  False referrals showed more variation, of between 
22 and 53 cases, until, after 34 COT test removals, their number fell dramatically to zero.  
Performance prior to removal of any COT tests (79% percentage Kappa, 32 false discharges and 
27 false referrals) was closely matched (78% percentage Kappa, 30 false discharges and 29 false 
referrals) after 30 removals, leaving just 11 COT tests.  Table 4.6 shows these tests, ranked in 
descending order, with their respective positive and negative LRs for all outcomes (shown also with 
their respective standard deviations).   
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Table 4.6 shows positive and negative LRs for the 11 COT tests remaining after removal of 30 
redundant tests.  Standard deviations (SD), expressed as a percentage of the mean, varied from <1 
to 52% (mean = 12%) for positive LRs and from <1 to 21% (mean = 3%). So LRs could vary 
substantially across the 10 folds of the cross-validation procedure.  The variation may have arisen 
due to differences in the numbers of cases exhibiting various test results in each fold; each fold 
being stratified for COT outcomes (Dis, Fup and Refer) rather than test outcomes.  
 
COT test 
Positive LR Negative LR 
Refer Fup Dis Refer Fup Dis 
HPA class: severe 
mean 164175 0.00 0.00 0.79 1.03 1.16 
SD (9235) (0.00) (0.00) (0.01) (0.00) (0.01) 
VCDR diff: >30 
 
mean 113214 0.00 0.00 0.86 1.02 1.11 
SD (6475) (0.00) (0.00) (0.01) (0.00) (0.01) 
GAT IOP: >32 
 
mean 50954 0.00 0.00 0.93 1.01 1.05 
SD (3591) (0.00) (0.00) (0.00) (0.00) (0.00) 
IOP diff: >6 
 
mean 84.88 1.07 0.00 0.82 1.00 1.15 
SD (30.15) (0.26) (0.00) (0.01) (0.01) (0.01) 
VCDR: >70 
 
mean 36.60 0.46 0.03 0.63 1.04 1.34 
SD (3.40) (0.11) (0.00) (0.01) (0.01) (0.01) 
HPA class: 
moderate 
mean 28.78 2.98 0.00 0.75 0.92 1.27 
SD (4.52) (0.45) (0.00) (0.02) (0.02) (0.02) 
GAT IOP: >25-32 
 
mean 24.10 3.06 0.01 0.76 0.92 1.25 
SD (3.20) (0.38) (0.00) (0.01) (0.01) (0.01) 
HPA class: mild 
 
mean 14.94 5.35 0.00 0.55 0.68 1.76 
SD (0.90) (0.37) (0.00) (0.02) (0.03) (0.05) 
IOP diff: 3 to 6 
 
mean 14.62 3.50 0.03 0.75 0.88 1.29 
SD (1.38) (0.19) (0.00) (0.01) (0.01) (0.02) 
Race: Hispanic 
 
mean 13.21 1.73 0.08 0.96 0.99 1.03 
SD (4.43) (0.69) (0.03) (0.01) (0.01) (0.01) 
VCDR diff: 20-30 
 
mean 5.08 2.49 0.17 0.66 0.82 1.45 
SD (0.33) (0.18) (0.01) (0.02) (0.02) (0.02) 
 
Table 4.6 Positive and negative likelihood ratios (LR) for the 11 COT tests after removal of 30 
redundant tests. The mean and standard deviation (SD) values shown were derived from the 10 
estimates of each likelihood ratio from randomised stratified tenfold cross-validation on the 1006 
pooled COT cases. COT tests are ranked on the basis of positive likelihood ratios for the Refer 
outcome. Key (alphabetical order): GAT = Goldmann Applanation Tonometry, HPA = Hodapp-
Parrish-Anderson classification, IOP = Intra-Ocular Pressure (mmHg), IOP diff = Intra-Ocular 
Pressure difference between eyes (mmHg), VCDR = Vertical Cup Disc Ratio (%), VCDR diff = 
Vertical Cup Disc Ratio (%) difference between eyes.    
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4.9 Ranking of COT tests 
Table 4.7 shows all COT tests listed in order of their highest ranking test outcome.  Those included 
in the top 11 appear in bold.  Table 4.7 also shows ranked positions and the frequencies for each 
tests result, allowing the reader can see the size of the samples from which LRs, used to establish 
ranks, were based.  The key COT test methods were VFA, VCDR, GAT and CCT.  Of these, only 
CCT could be considered redundant.  This is surprising, given its influence on GAT.  All HPA 
classifications were included in the top 11 tests.  It was surprising was that VDS did not make it into 
the top 11, given its influence on the interpretation of VCDR.  The inhomogeneity between the 3 
optometrists for VDS may account for this.  The GAT test method included observations relating to 
IOP and IOP diff. Both of these made it into to the top 11 but the finding that IOPs of lower than 
25mmHg were irrelevant was surprising; maybe the referral cut-off for IOP of 21mmHg is too low. 
That race (Hispanic) made it into the top 11 was a surprise given that vast majority of cases were 
Caucasian.  Perhaps the low frequency of Hispanic cases was responsible for this.  Likewise, the 
ranking of Afro-Caribbeans below Caucasian seems to be an aberration, perhaps also due to the 
low frequency of the former.  It appears that age, RFR, sex and FH could all be considered as 
redundant to COT decisions, though age (80+ years) narrowly missed redundancy, being ranked 
12th.  It is interesting that RFR classes are ranked in roughly the same order as the equivalent COT 
test; being, in descending order, suspected visual fields, optic discs and IOPs.  The real surprise is 
that FH falls lowest in the list.   
The rankings shown on Table 4.7 broadly agree with those based on Chi-square (Table 3.4) but 
differences of up to five ranking positions arose.  
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Rankings based on likelihood ratios (Table 4.7) showed slightly better agreement with those based 
on Chi square (Table 3.4, method A; mean and range of differences in ranked position = 1.42, 0 to 
4) than those based on Chi-square per degree of freedom (Table 3.4, method B; mean and range of 
differences in ranked position = 1.58, 0 to 5). 
 
                COT test 
Test outcome 
rank, frequency 
HPA class Severe 
1, 29 
Moderate 
6, 44 
Mild 
8, 91 
VCDR diff >30 
2, 20 
20-30 
11, 121 
<20  
36, 865 
GAT IOP >32  
3, 9 
>25-32  
7, 43 
21-25  
15, 
181 
<21 
39,773 
IOP diff >6  
4, 27 
3-6 
9, 53 
<3 
35, 926 
VCDR >70 
5, 71 
50-70  
23, 449 
<50 
39, 496 
Race Hispanic 
10, 9 
African 
13, 3 
Asian 
19, 
17 
Caucasian  
24, 965 
Afro-
Caribbean 
33, 12 
Age 80+  
12, 78 
70-79  
16, 218 
60-69  
25, 
275 
40-49  
32, 135 
50-
59  
38, 
242 
<40    
40, 
60 
RFR 
 
Suspect visual fields 
14, 199 
Suspect optic 
discs  
18, 452 
Suspect 
IOPs 
30, 462 
CCT <555  
17, 443 
555-590  
37, 374 
>590  
41, 189 
Sex Male 
20, 482 
Female  
27, 524 
VDS 1.4-1.7 
 21, 439 
<1.4  
22, 87 
1.8+  
29, 480 
FH Sibling  
28, 62 
Father  
31, 110 
Mother  
34, 143 
 
Table 4.7 COT tests listed in order of their highest ranking test outcome. Ranks shown are   based 
on positive likelihood ratios for the Refer outcome. The frequency of each test outcome is also shown. 
Test outcomes included in the top 11 (Table 4.6) are shown in bold. Key (alphabetical order): CCT = 
Central Corneal Thickness (microns), GAT = Goldmann Applanation Tonometry, HPA = Hodapp-
Parrish-Anderson classification, IOP = Intra-Ocular Pressure (mmHg), IOP diff = Intra-Ocular 
Pressure difference between eyes (mmHg), RFR = Reason for Visit, VCDR = Vertical Cup Disc Ratio 
(%), VCDR diff = Vertical Cup Disc Ratio (%) difference between eyes, VDS = Vertical Disc Size 
(mm).  
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All three ranking methods agreed in placing HPA class at the top of the list and family history at the 
bottom.  The low ranking of RFR (ranked 6th to 8th), CCT (ranked 7th to 9th), sex (ranked 10th to 11th) 
and VDS (ranked 9th to 11th) was also consistently found.  The biggest discrepancy related to race in 
which rankings based on Chi-square (10th to 11th) seemed more representative than that based on 
likelihood ratios (6th); given that races other than Caucasians were poorly represented in the 
populations seen by the COT optometrists. 
 
4.10 Summary 
 
The findings presented in this chapter indicate that: 
COT tests did not adhere to the naïve Bayes’ assumption of independence.  Section 4.3 showed 
that the 12 COT tests included in this study showed statistically significant inter-correlations.  As 
such the basic assumption of independence upon which naïve Bayes’ assumes was violated.  
Naïve Bayes learned rapidly.  Learning curves shown in section 4.4 showed that, despite violations 
of the assumption of independence, naïve Bayes learned rapidly and achieved maximum Rand 
accuracy, consistently requiring fewer than 69 cases to do so. 
Likelihood ratios generated from just 69 cases had limited transferability Section 4.5 showed that 
LRs generated from the first 69 cases of each COT were not as transferable as had been hoped for.  
They caused a drop in Rand accuracy from 0.97-0.98 to 0.81-0.90 and Kappa from 0.83-0.91 to 
0.18 to 0.63.   
Bayes cannot safely predict the decisions of COT optometrists.  Findings presented in section 4.6 
indicated that, based on the 1006 cases pooled from all three COT optometrists, the maximum 
Rand accuracy of Bayes was 0.96 (Kappa 0.79) but a more realistic estimate, from randomised 
stratified tenfold cross-validation, amounted to a Rand accuracy of 0.95 (Kappa 0.75).  
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Informedness reflected variation in the area under the ROC curve while markedness (which of 
greater importance to making predictions) reflected variations in Matthew’s correlation coefficient.  
These alternative measures of performance showed greater variations than seen for Rand 
accuracy.  These and a confusion matrix indicated that false discharge and referral rates were, 
despite being less than 5%, unacceptably high.  Attempts to remedy this by making Bayes cost 
sensitive failed as they caused too many unnecessary follow ups and would have rendered the COT 
not cost effective.  
Likelihood ratios derived from the pooled COT cases were more transferable.  Transferability was 
revisited in section 4.7.  Findings indicated that LRs generated from the 1006 pooled cases, and 
tested on the first 69 cases of each COT optometrist, were more transferable than had been found 
in section 4.5.  Nevertheless, false discharges and referrals were still unacceptably high. 
Likelihood ratios are a useful means of investigating redundancy.  Work presented in section 4.8 
showed how LRs could be used to identify redundancy in the COT test outcomes.  Thirty COT test 
findings could be removed with little change to Rand accuracy or Kappa.  Visual field analysis, optic 
nerve head assessment and GAT were, as might be expected, most useful.  Apart from race, which 
might have been an aberration, none of the other COT tests needed to have been included.  
That this included central corneal thickness and vertical optic disc size came as a surprise, as did 
finding family history of POAG at the bottom of the list.  
Broad agreement was found when ranking COT tests based on likelihood ratios (Table 4.7) or Chi-
square (Table 3.4).  Chi-square ranking methods did, however, appear to better reflect the influence 
of race that was poorly represented in the study sample.  
Chapter 5 provides a summary of the key findings of this thesis, its limitations and recommendations 
for future work. 
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Chapter 5:  Study findings and limitations with recommendations for further work 
5.1 Introduction  
A summary of the key findings and limitations of the present study is provided in this chapter 
together with recommendations for future research. 
5.2 Key findings 
This study was designed to determine whether artificial intelligence based on naïve Bayes could 
replicate the clinical decisions made by experienced optometrists using a structured SOP.  Previous 
research carried out Aston (1) had shown that use of unstructured clinical data limited the accuracy 
of naïve Bayes. 
The structured clinical data presented in this thesis was that collected by three highly trained 
optometrists working for the West Kent CCG COT.  An opportunity arose to determine how effective 
these optometrists were in the referral refinement of COAG. 
Naïve Bayes had been used before in ophthalmic research (section 1.2) and, more specifically, in 
glaucoma research (section1.3) but had not, as far as the author and his supervisory team were 
aware, been applied to the referral refinement of COAG (section 1.4).  This was one element of the 
study that is claimed to have made a substantial and original contribution to the literature. 
The application of naive Bayes in this study was based on calculations described by the Oxford 
Centre for Evidence Based Medicine (section 1.4.1) but adds Laplacian correction (section 1.4.2), 
the evaluation of learning curves using the AEL Bayes application (section 1.4.3) and multiple cut-
off points (section 1.4.4).  
 
 
 
105 
Laplacian correction has been applied many times before in the literature (1) but the study of 
learning curves and the use of multiple cut-off points has not been described before, especially in 
relation to clinical decision support in the referral refinement of COAG. 
Reviews of the glaucoma research deemed relevant to the present study (section 1.5), NICE 
guidelines for the diagnosis, management and treatment of COAG (section 1.6) and existing 
glaucoma referral refinement schemes (section 1.7) were influential in the development of the 
structured SOP used by West Kent CCG COT practitioners (section 1.8). 
The study described in this thesis was treated as a clinical audit for the purposes of ethical data 
collection without the consent of the people referred into the COT (section 2.2).  Data analysed in 
this study were collected from 1006 people seen by the three COT optometrists over one year 
(section 2.3).  The rationale behind the structured SOP and multiple cut-off points adopted were 
described in detail (sections 2.3.1 to 2.3.10). 
Preliminary analyses of the data were carried out in chapter 3.  These analyses explored the 
distribution of the COT’s clinical test findings, according to the multiple cut-off points introduced in 
chapter 2, for the three optometrists contributing data to this study (sections 3.3 and 3.4).  Six out of 
the 13 COT clinical tests showed inhomogeneous distributions between the COT optometrists that 
could, potentially, have reduced the consistency of naïve Bayesian learning (Table 3.2).  
Associations between each clinical test and the COT management outcomes were also explored 
(section 3.5).   
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All but one of the findings (that relating to VDS) corroborated previous research (Table 3.3).  Here, 
referral rates increased as VDS reduced, which disagreed with one study (149) that had found no 
evidence for optic disc size being a risk factor for COAG.  The discrepancy may have resulted from 
the use of univariate analyses in the present study that could be prone to confounding. 
Inhomogeneity in VDS distributions found by each COT optometrist also suggests that differences 
in the criteria used by each optometrists to judge VDS may have contributed to this discrepancy.  
Findings summarised in Table 3.3 also indicated that study of the influence of race on COT 
decisions was limited as the sample was predominantly Caucasian.  Referrals to the COT were 
more likely to indicate COAG if based on multiple RFRs. 
A cluster of investigations were carried out to explore relationships between various COT tests 
(sections 3.6 to 3.8).  These showed that (a) GAT IOP increased with CCT, as had been reported in 
previous studies, but not explain observed differences in referrals made to the COT for raised IOP 
and COT measurements of IOP (section 3.6), (b) VCDR increased with VDS, as had been reported 
in the previous literature (section 3.7) and (c) observed differences between referrals made to the 
COT for suspect VF and COT measurements of HPA were considered to arise from the varied VF 
testing methods used by community optometrists (section 3.8). 
Investigation of the effectiveness of COAG referral refinement by the COT optometrists contributing 
data to the present study (section 3.9) showed that FDRs compared favourably to those reported for 
other GRR schemes, with estimated cost savings of £54 per case. 
Naïve Bayes was applied to the COT data in chapter 4.  The COT tests showed statistically 
significant inter-correlations (section 4.3) and, therefore, violated the basic assumption of 
independence upon which naïve Bayes’ rests.  
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Nevertheless, naïve Bayes learned rapidly and consistently achieved maximum Rand accuracy of at 
least 97% (Kappa 0.83) when trained on as few 69 cases (section 4.4).  However, likelihood ratios 
generated from the learning process had limited transferability (section 4.5) and caused a drop in 
Rand accuracy to 81% (Kappa 0.37), which could, in part, have been due to the inhomogeneous 
distributions in COT test results described earlier (as detailed in Table 3.2).  Transferability 
improved when likelihood ratios were based on learning from all 1006 cases (section 4.7).   
Findings presented in section 4.6 indicated that naïve Bayes could not safely predict the decisions 
of COT optometrists.  Based on all 1006 cases, the maximum Rand accuracy was 0.96 (Kappa 
0.79) but a more realistic estimate, from randomised stratified tenfold cross-validation, amounted to 
a Rand accuracy of 0.95 (Kappa 0.75).  Though accuracy was reasonably high, false discharge and 
referral rates were, despite being less than 5%, unacceptable.  Attempts to remedy this by making 
naïve Bayes’ cost sensitive failed as they caused too many unnecessary follow ups and would have 
rendered the COT not cost effective.  
Interestingly, findings shown in section 4.6 also revealed that alternative measures of accuracy 
(informedness, the area under the ROC curve, markedness and Matthew’s correlation coefficient) 
showed greater variations than seen for Rand accuracy and may be worth further exploration in the 
future. 
Findings presented in section 4.8 showed how likelihood ratios could be used to identify redundancy 
in the COT test outcomes.  Thirty COT test findings could be removed with little change to Rand 
accuracy or Kappa. Visual field analysis, optic nerve head assessment and Goldmann Applanation 
tonometry were, as might be expected, most useful.  
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Apart from race, which might have been an aberration, none of the other COT tests needed to have 
been included.  That this included central corneal thickness and vertical optic disc size came as a 
surprise, as did finding family history of COAG at the bottom of the list. 
Broad agreement was found when ranking COT tests based on likelihood ratios (section 3.10) or 
Chi-square (section 4.9).  Chi-square ranking methods did, however, appear to better reflect the 
influence of race, which was poorly represented in the study sample. 
5.3 Study limitations 
The reader should be aware of important limitations to this study. 
The Standards for Reporting of Diagnostic Accuracy (STARD) guidelines were developed to 
improve the reporting quality of the diagnostic accuracy of studies (198).  This study was not 
designed with reference to these guidelines, while the use of 2x 2 tables, sensitivity and specificity 
do conform to STARD not all the points are adhered to which is a limitation of this study. 
All three COT optometrists were Independent Prescribers with a Special Interest in Ophthalmology.  
They were regularly re-accredited.  The optometrists confirmation of their decisions by a consultant 
ophthalmologist would have been desirable but was not feasible and would have made the COT 
unworkable. 
The conclusions of this study are entirely based on naïve Bayes. Although Witten et al. (192) have 
indicated that a Bayes learning scheme may perform just as well as more sophisticated machine 
leaning methods, no attempt was been made in this study to confirm this. 
The ethnicity of the sample does not allow for judgements to be made on any other ethnic group 
than Caucasian. 
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The lack of agreement between observers, particularly in VDS is an important limitation of the study. 
Outcomes of the COT tests were grouped, according to the literature and NICE guidelines. This 
approach to the study may have limited its findings.  More sophisticate machine learning methods 
are available to determine which groupings lead to best performance but were not explored in this 
study. 
The level of myopia, which increases the risk of COAG (199, 200), was not included in this study as 
the refractive correction was not always known from the community optometrist referral.  Equally, 
many of the more elderly subjects were pseudophakic, following cataract surgery, so that the extent 
of myopia that they had prior to surgery, which may have raised the risk of COAG, was also 
unknown. 
All COT tests were carried out at a single COT visit, importantly this leads to limitation with respect 
to RTM  which may bias an investigation when it is based upon an initial value without a control 
group (183).  For example in this study IOP was measured at one given time.  GAT IOP is known to 
have diurnal variations (184), with 65% of peak pressures occurring before noon (201).  Therefore 
the analysis would have neglected to account for diurnal variations, inter-observer and intra-
observer variability.  This may mean that subjects classified as suspect COAG during the single visit 
may, at another time, be classified as normal and discharged or may have been followed up; either 
way, the COT management outcome will have varied. 
It is possible that the SOP adopted by the COT added an issue of circularity to the findings.  If COT 
decisions were based on strict rules, then it is possible that naïve Bayes would merely show up 
relationships that reflected these.  No attempt was made to explore this possibility as a mechanisms 
for doing so could not be devised. 
The exploration of redundancy in section 4.8 was based on COT tests ranked purely on the basis of 
positive likelihood ratios for the referral outcome.   
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Ranking could have been based on negative likelihood ratios or some ranking index based on a 
combination of both. Ranking could also have been based on the other COT outcomes (discharge 
and follow-up) or, again, some ranking index based on all three.  Additional investigation of these 
alternative ranking indices would have been ideal but, given that application of naïve Bayes was 
considered unsafe for use by the COT (see section 4.6), restricting analyses to positive likelihood 
ratios for the referral outcome was deemed sufficient. 
This study has shown that 79% of the referrals from community optometrists were discharged, 
thereby representing the high false positive rate expected when screening for a rare eye condition 
such as COAG.  An analysis of which community optometrist referrals were least prone to false 
positive errors would have been valuable but the precise details of these referrals were not recorded 
in this study.  For example, was a referral for suspected IOP based on a pressures of >21mmHg or 
higher?  Or was referral based on intraocular differences in IOP?  The same uncertainties apply to 
referrals for suspect optic discs and visual fields.   
A gross examination of referrals revealed that those based on suspect optic discs had the greatest 
number of false positives (86%, 301 out of 351 referrals) while those based on suspect optic discs 
and visual fields had the lowest (30%, 16 out of 53 referrals).  Such a study could have provided 
very useful indicators for how to improve referrals by community optometrists. 
5.4 Recommendations for further research 
The findings presented in this thesis indicate that naïve Bayes cannot safely predict the decisions of 
COT optometrists for referral refinement of COAG.  
Naïve Bayes was only used in this study and more sophisticated Bayes and machine learning 
classifiers were beyond the scope of this thesis.  Future research could investigate the use of more 
sophisticated Bayes and machine learning classifiers to determine if false discharge and referral 
rates may be reduced. 
111 
 
Future plans include extending the application of naïve Bayes to other less serious ophthalmic 
conditions such as in the differential diagnosis of red eye such as conjunctivitis seen by the West 
Kent CCG COT.  
5.5 Summary  
For now at least the findings of this study indicate that a naïve Bayesian classifier is not a substitute 
for an experienced specialist clinician when evaluating a patient for the possible presence of a sight 
threating condition such as COAG.  This form of Bayesian classifier however may lend its self to 
other applications such as staff training, helping clinicians triage referrals and developing 
accreditation models in different levels of service.  
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